<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL document created with XMark (C) by Bowne Inc. -->
<!-- Based on XBRL 2.1 -->
<!--Merged instance document: \\192.168.211.93\xbrl\Note Extraction (Please do not delete)\AUGUST 2009\6Aug night\bsx-v3\bsx-20090630.xml-->
<!--merged on: 8/7/2009 12:39:58 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:bsx="http://bostonscientific.com/20090630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://xbrl.us/us-gaap/2009-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.us/dei/2009-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="bsx-20090630.xsd" />
  <!-- Context Section -->
  <context id="TwelveMonthEnded_31Dec2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <instant>2008-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Jul2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <instant>2009-07-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Jun2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <instant>2009-06-30</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <startDate>2009-04-01</startDate>
      <endDate>2009-06-30</endDate>
    </period>
  </context>
  <context id="ThreeMonthsEnded_30Jun2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <startDate>2008-04-01</startDate>
      <endDate>2008-06-30</endDate>
    </period>
  </context>
  <context id="SixMonthsEnded_30Jun2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-06-30</endDate>
    </period>
  </context>
  <context id="January-01-2009_June-30-2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000885725</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-06-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;NOTE A &amp;#8212; BASIS OF PRESENTATION&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The accompanying unaudited condensed consolidated financial statements of Boston Scientific
   Corporation have been prepared in accordance with accounting principles generally accepted in the
   United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q
   and Article&amp;#160;10 of Regulation&amp;#160;S-X. Accordingly, they do not include all of the information and
   footnotes required by U.S. GAAP for complete financial statements. In the opinion of management,
   all adjustments (consisting only of normal recurring adjustments) considered necessary for fair
   presentation have been included. Operating results for the six months ended June&amp;#160;30, 2009 are not
   necessarily indicative of the results that may be expected for the year ending December&amp;#160;31, 2009.
   For further information, refer to the consolidated financial statements and footnotes thereto
   included in our 2008 Annual Report on Form 10-K.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation. See
   &lt;i&gt;Note M &amp;#8212; Segment Reporting &lt;/i&gt;for further details.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:FairValueDisclosuresTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE B &amp;#8212; FINANCIAL INSTRUMENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;b&gt;&lt;i&gt;Derivative Instruments and Hedging Activities&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We develop, manufacture and sell medical devices globally and our earnings and cash flows are
   exposed to market risk from changes in currency exchange rates and interest rates. We address these
   risks through a risk management program that includes the use of derivative financial instruments,
   and operate the program pursuant to documented corporate risk management policies. We recognize all
   derivative financial instruments in our consolidated financial statements at fair value in
   accordance with Financial Accounting Standards Board (FASB)&amp;#160;Statement No.&amp;#160;133, &lt;i&gt;Accounting for
   Derivative Instruments and Hedging Activities&lt;/i&gt;. In accordance with Statement No.&amp;#160;133, for those
   derivative instruments that are designated and qualify as hedging instruments, the hedging
   instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash
   flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in
   the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been
   designated and qualifies as part of a hedging relationship and, further, on the type of hedging
   relationship. Our derivative instruments do not subject our earnings or cash flows to material
   risk, as gains and losses on these derivatives generally offset losses and gains on the item being
   hedged. We do not enter into derivative transactions for speculative purposes and we do not have
   any non-derivative instruments that are designated as hedging instruments pursuant to Statement
   No.&amp;#160;133.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Currency Hedging&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We are exposed to currency risk consisting primarily of foreign currency denominated monetary
   assets and liabilities, forecasted foreign currency denominated intercompany and third party
   transactions and net investments in certain subsidiaries. We use non-derivatives (primarily
   European manufacturing operations) and derivatives (currency forward and option contracts) to
   reduce the risk that our earnings and cash flows associated with these foreign currency denominated
   balances and transactions will be adversely affected by currency exchange rate changes.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Designated Foreign Currency Hedges&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;All of our designated currency hedge contracts outstanding as of June&amp;#160;30, 2009 and December&amp;#160;31,
   2008 were cash flow hedges under Statement No.&amp;#160;133. We record the effective portion of any change
   in the fair value of foreign currency cash flow hedges in other comprehensive income (OCI)&amp;#160;until
   the related third-party transaction occurs. Once the related third-party transaction occurs, we
   reclassify the effective portion of any
   related gain or loss on the foreign currency cash flow hedge to earnings. In the event the hedged
       forecasted transaction does not occur, or it becomes probable that it will not occur, we would
       reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.
   We had currency derivative instruments designated as cash flow hedges outstanding in the contract
       amount of $2.693&amp;#160;billion as of June&amp;#160;30, 2009 and $2.587&amp;#160;billion as of December&amp;#160;31, 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We recognized in earnings net gains of $8&amp;#160;million on our cash flow hedges during the second quarter
       of 2009 and $24&amp;#160;million for the first half of 2009. All currency cash flow hedges outstanding as
       of June&amp;#160;30, 2009 mature within 36&amp;#160;months. As of June&amp;#160;30, 2009, $4&amp;#160;million of net losses, net of
       tax, were recorded in accumulated other comprehensive income (AOCI)&amp;#160;to recognize the effective
       portion of the fair value of any currency derivative instruments that are, or previously were,
       designated as foreign currency cash flow hedges, as compared to net losses of $6&amp;#160;million as of
       December&amp;#160;31, 2008. As of June&amp;#160;30, 2009, $10&amp;#160;million of net losses, net of tax, may be reclassified
       to earnings within the next twelve months.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The success of our hedging program depends, in part, on forecasts of transaction activity in
       various currencies (primarily Japanese yen, Euro, British pound sterling, Australian dollar and
       Canadian dollar). We may experience unanticipated currency exchange gains or losses to the extent
       that there are differences between forecasted and actual activity during periods of currency
       volatility. Changes in currency exchange rates related to any unhedged transactions may impact our
       earnings and cash flows.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Non-designated Foreign Currency Contracts&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of
       offsetting transactions and balances. We use currency forward contracts as a part of our strategy
       to manage exposure related to foreign currency denominated monetary
       assets and liabilities and certain short-term earnings and cash flow exposures related to our Japanese operations that do not qualify for hedge accounting under Statement No.&amp;#160;133. These
       currency forward contracts are not designated as cash flow, fair value or net investment hedges
       under Statement No.&amp;#160;133; are marked-to-market with changes in fair value recorded to earnings; and
       are entered into for periods consistent with currency transaction exposures, generally one to six
       months. We had currency derivative instruments not designated as hedges under Statement No.&amp;#160;133
   outstanding in the contract amount of $1.832&amp;#160;billion as of June&amp;#160;30, 2009 and $1.809&amp;#160;billion as of
       December&amp;#160;31, 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Interest Rate Hedging&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Our interest rate risk relates primarily to U.S. dollar borrowings, partially offset by U.S. dollar
       cash investments. We use interest rate derivative instruments to manage our earnings and cash flow
       exposure to changes in interest rates by converting floating-rate debt into fixed-rate debt or
       fixed-rate debt into floating-rate debt.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We designate these derivative instruments either as fair value or cash flow hedges under Statement
       No.&amp;#160;133. We record changes in the fair value of fair value hedges in other, net, which is offset by
       changes in the fair value of the hedged debt obligation to the extent the hedge is effective.
   Interest payments made or received related to our interest rate derivative instruments are included
       in interest expense. We record the effective portion of any change in the fair value of derivative
       instruments designated as cash flow hedges as unrealized gains or losses in OCI, net of tax, until
       the hedged cash flow occurs, at which point the effective portion of any gain or loss is
       reclassified to earnings. All of our interest rate swap contracts outstanding as of June&amp;#160;30, 2009
   and December&amp;#160;31, 2008 were designated as cash flow hedges in accordance with Statement No.&amp;#160;133.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We had
       floating-to-fixed interest rate swap contracts indexed to three-month LIBOR outstanding in the
       notional amount of $4.100&amp;#160;billion as of June&amp;#160;30, 2009 and $4.900&amp;#160;billion as of December&amp;#160;31, 2008.
   The objective of these derivative instruments is to hedge against potential variability in our future
       interest payments on our expected LIBOR-indexed floating-rate loans as a result of changes in LIBOR.
   Three-month LIBOR approximated 0.595&amp;#160;percent as of June&amp;#160;30, 2009 and 1.425&amp;#160;percent as of December
       31, 2008. These interest rate swap contracts fix the interest rate on $2.200 billion of our expected LIBOR-indexed
       floating-rate loans for the remainder of 2009
   at approximately 2.72 percent, and $1.900 billion of our expected 2010 loans at approximately 2.08 percent.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition, in prior years we terminated certain interest rate derivative instruments, including
       fixed-to-floating interest rate swap contracts and floating-to-fixed treasury locks. We are amortizing the
       related gains and losses realized upon termination into earnings over the term of the hedged debt
       in accordance with Statement No.&amp;#160;133.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We recognized in earnings $10&amp;#160;million of net losses related to our currently outstanding and
       previously terminated interest rate derivative contracts for the second quarter of 2009, and $23
   million of net losses in the first half of 2009. As of June&amp;#160;30, 2009, $13&amp;#160;million of net losses,
       net of tax, are recorded in AOCI to recognize the effective portion of our interest rate derivative
       contracts, as compared to $20&amp;#160;million of net losses as of December&amp;#160;31, 2008. As of June&amp;#160;30, 2009,
   $16&amp;#160;million of net losses, net of tax, may be reclassified to earnings within the next twelve
       months.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Counterparty Credit Risk&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We do not have significant concentrations of credit risk arising from our derivative financial
       instruments, whether from an individual counterparty or group of counterparties. We reduce our
       concentration of counterparty credit risk on our derivative instruments by limiting acceptable
       counterparties to a diversified group of major financial institutions with investment grade credit
       ratings, limiting the amount of credit exposure by each counterparty to $50&amp;#160;million, and by
       actively monitoring their credit ratings and outstanding positions on an on-going basis.
   Furthermore, none of our derivative transactions are subject to collateral or other security
       arrangements and do not contain provisions that are dependent on our credit ratings from any credit
       rating agency.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We also employ master netting arrangements that reduce our counterparty payment settlement risk on
       any given maturity date to the net amount of any receipts or payments due between us and the
       counterparty financial institution. Thus, the maximum loss due to credit risk by counterparty is
       limited to the unrealized gains in such contracts net of any unrealized losses should any of these
       counterparties fail to perform as contracted. Although these protections do not eliminate
       concentrations of credit, as a result of the above considerations, we do not consider the risk of
       counterparty default to be significant.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Fair Value of Derivative Instruments&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following tables present the effect of our derivative instruments designated as cash flow
       hedges and those not designated as hedging instruments under Statement No.&amp;#160;133 on our unaudited
       condensed consolidated statement of operations for the second quarter and first half of 2009 (in
       millions).
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 8pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="40%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amount of Gain&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amount of Gain&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amount of Gain (Loss)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Loss) Recognized&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Loss) Reclassified&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Recognized in Earnings&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;in OCI&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;from AOCI into&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;on&lt;/b&gt; &lt;b&gt;Ineffective Portion and&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Effective&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Earnings&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Location in Statement of&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Amount Excluded from&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Location in Statement of&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 7pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Cash Flow Hedges&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Portion), (pre tax)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(Effective Portion)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Operations&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Effectiveness Testing (*)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Operations&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="21" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;&lt;u&gt;Three Months Ended June&amp;#160;30,
   2009&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Interest rate swap contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(10&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)**&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" nowrap="nowrap" align="center"&gt;Interest expense&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency hedge contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(101&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="center"&gt;Cost of products sold&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(107&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(2&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;&lt;u&gt;Six
   Months Ended June&amp;#160;30, 2009&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Interest rate swap contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(20&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)**&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" nowrap="nowrap" align="center"&gt;Interest expense&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)***&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" nowrap="nowrap" align="center"&gt;Interest expense&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency hedge contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;27&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;24&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="center"&gt;Cost of products sold&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="2" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;19&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(2&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000; border-top: 0px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000; border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Other than described in ***, the amount of gain (loss)&amp;#160;recognized in earnings related to the ineffective portion of hedging relationships was de minimis in the second quarter and first half of 2009.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;**&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;We had $12&amp;#160;million of gains recorded in AOCI as of June&amp;#160;30, 2009 related to floating-to-fixed treasury locks terminated during 2005 and 2006. We
   recognized approximately $1&amp;#160;million as a reduction in interest expense during the first half of 2009 related to
   these instruments.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;***&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;During the first quarter of 2009, we prepaid $500&amp;#160;million of our term loan debt, and recognized $2&amp;#160;million of ineffectiveness in accordance with Statement No.&amp;#160;133 on interest rate swaps for which
   there was no longer an underlying exposure.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="24%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="25%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="25%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Amount of Gain (Loss)&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Recognized in Earnings&lt;/b&gt; (in millions)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Location&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;b&gt;Derivatives Not Designated as&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;in Statement of&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Ended&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #ffffff"&gt;&lt;b&gt;Hedging Instruments&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #ffffff"&gt;&lt;b&gt;Operations&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;June 30, 2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;June 30, 2009&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="13" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency hedge contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="center"&gt;Other, net&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(20&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;33&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency hedge  contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="center" nowrap="nowrap"&gt;Cost of products sold&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;(21&lt;/b&gt;&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;32&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160; &amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Losses&amp;#160;and
       gains on currency hedge contracts not designated as hedged
       instruments&amp;#160;were&amp;#160;substantially offset by $22&amp;#160;million in gains from foreign currency transaction
       exposures&amp;#160;during the second quarter of 2009&amp;#160;and&amp;#160;by $37&amp;#160;million&amp;#160;in losses&amp;#160;on foreign currency
       transaction exposures&amp;#160;for the first half of 2009.&amp;#160; As a result, we recorded a net foreign currency
       gain of $2&amp;#160;million during the second quarter of 2009 and&amp;#160;a net foreign currency loss of $4&amp;#160;million
       during the first half of 2009 within other, net in our accompanying unaudited condensed
       consolidated financial statements.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We did not have fair value hedges or net investment hedges outstanding as of June&amp;#160;30, 2009.
   However, prior to 2006, we entered into fixed-to-floating interest rate swaps, which we designated
       as fair value hedges under Statement No.&amp;#160;133. We terminated these hedges during 2006 and, as of
       June&amp;#160;30, 2009, the carrying amount of certain of our senior notes included $3&amp;#160;million of
       unamortized gains and $9&amp;#160;million of unamortized losses related to these interest rate swaps. We
       recognized approximately $1&amp;#160;million of interest expense during the first half of 2009 related to
       these instruments.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Statement No.&amp;#160;133 requires all derivative instruments to be recognized at their fair values as
       either assets or liabilities on the balance sheet. We determine the fair value of our derivative
       instruments using the framework prescribed by FASB Statement No.&amp;#160;157, &lt;i&gt;Fair Value Measurements&lt;/i&gt;, by
       considering the estimated amount we would receive to sell or transfer these instruments at the
       reporting date and by taking into account current interest rates, currency exchange rates, the
       creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In
       certain instances, we may utilize financial models to measure fair value. Generally, we use inputs
       that include quoted prices for similar assets or liabilities in active markets; quoted prices for
       identical or similar assets or liabilities in markets that are not active; other observable inputs
       for the asset or liability; and inputs derived principally from, or corroborated by, observable
       market data by correlation or other means. As of June&amp;#160;30, 2009, we have classified all of our
       derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by
       Statement No.&amp;#160;157, as discussed below, because these observable inputs are available for
       substantially the full term of our derivative instruments.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following table presents the fair value of our derivative instruments as they appear in our
       unaudited condensed consolidated balance sheets as of June&amp;#160;30, 2009 by type of contract and whether
       it is a qualifying
       hedge under Statement No.&amp;#160;133.
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="39%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="50%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Location in&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Balance Sheet&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30, 2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="7" valign="top" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;&lt;b&gt;Derivative Assets:&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;&lt;u&gt;Designated
   Hedging Instruments&lt;/u&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Prepaid expenses and other current assets&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;31&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other long-term assets&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;27&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;58&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;&lt;u&gt;Non-Designated
   Hedging Instruments&lt;/u&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency
   Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Prepaid expenses and other current assets&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;&lt;b&gt;Total Derivative Assets&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;70&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;&lt;b&gt;Derivative Liabilities:&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;&lt;u&gt;Designated Hedging Instruments&lt;/u&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other current liabilities&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;43&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other long-term liabilities&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Interest Rate Swap Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other current liabilities&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;26&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Interest Rate Swap Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other long-term liabilities&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;94&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;&lt;u&gt;Non-Designated Hedging Instruments&lt;/u&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td align="left" valign="top"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Currency Hedge Contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;Other current liabilities&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;23&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;&lt;b&gt;Total Derivative Liabilities&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;117&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td align="left" valign="top"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Other Fair Value Measurements&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On a recurring basis, we measure certain financial assets and financial liabilities at fair value
       based upon quoted market prices, where available. Where quoted market prices or other observable
       inputs are not available, we apply valuation techniques to estimate fair value. Statement No.&amp;#160;157
   establishes a three-level valuation hierarchy for disclosure of fair value measurements. The
       categorization of financial assets and financial liabilities within the valuation hierarchy is
       based upon the lowest level of input that is significant to the measurement of fair value. The
       three levels of the hierarchy are defined as follows:
   &lt;/div&gt;
   &lt;div style="margin-top: 6pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="2%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Level 1 &amp;#8212; Inputs to the valuation methodology are quoted market
   prices for identical assets or liabilities.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 6pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="2%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Level 2 &amp;#8212; Inputs to the valuation methodology are other
   observable inputs, including quoted market prices for similar
   assets or liabilities and market-corroborated inputs.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 6pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="2%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Level 3 &amp;#8212; Inputs to the valuation methodology are unobservable
   inputs based on management&amp;#8217;s best estimate of inputs market
   participants would use in pricing the asset or liability at the
   measurement date, including assumptions about risk.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Our investments in money market funds, as well as available-for-sale investments carried at fair
       value, are generally classified within Level 1 of the fair value hierarchy because they are valued
       using quoted market prices. Our money market funds are classified as cash and cash equivalents
       within our accompanying unaudited condensed consolidated balance sheets, in accordance with our
       accounting policies, as these funds are highly liquid and readily convertible to known amounts of
       cash.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Financial assets and financial liabilities measured at fair value on a recurring basis consist of
       the following as of June&amp;#160;30, 2009:
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="17" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Assets&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Money market funds
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;564&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;564&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Available-for-sale investments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency and interest rate hedge contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;70&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;70&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="15" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;565&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;70&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;635&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="15" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Liabilities&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Currency and interest rate hedge contracts
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;117&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;117&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="15" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;117&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;117&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="15" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition to $564&amp;#160;million invested in money market funds as of June&amp;#160;30, 2009, we had $504&amp;#160;million
       of cash invested in short-term time deposits, and $126&amp;#160;million in interest bearing and non-interest
       bearing bank accounts.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in
       periods subsequent to initial recognition. The fair value of a cost method investment is not
       estimated if there are no identified events or changes in circumstances that may have a significant
       adverse effect on the fair value of the investment. The aggregate carrying amount of our cost
       method investments was $69&amp;#160;million as of June&amp;#160;30, 2009 and $67&amp;#160;million as of December&amp;#160;31, 2008. Our
       assets and liabilities measured at fair value on a non-recurring basis using significant
       unobservable inputs (Level 3) were $7&amp;#160;million as of June&amp;#160;30, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The fair value of our debt obligations was $5.965&amp;#160;billion as of June&amp;#160;30, 2009 and $6.184&amp;#160;billion as
       of December&amp;#160;31, 2008. Refer to &lt;i&gt;Note D &amp;#8212; Borrowings and Credit Arrangements &lt;/i&gt;for a discussion of our
       debt obligations.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <bsx:SupplementalBalanceSheetInformationTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 3 - bsx:SupplementalBalanceSheetInformationTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE C &amp;#8212; SUPPLEMENTAL BALANCE SHEET INFORMATION&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following are the components of various balance sheet items as of June&amp;#160;30, 2009 and December
   31, 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Inventories&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Finished goods
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;562&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;555&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Work-in-process
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;137&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;135&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Raw materials
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;179&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;163&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;878&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;853&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Sales of the PROMUS&amp;#174; everolimus-eluting stent system represented approximately eight percent of our
   total net sales for the first half of 2009. We are reliant on Abbott Laboratories for our supply of
   everolimus-eluting stent systems, including any improvements or
   iterations approved for sale during the term of the applicable supply
   arrangements and of the type that could be approved by a supplement
   to an approved FDA pre-market approval. Any production or capacity issues that affect Abbott&amp;#8217;s manufacturing
   capabilities or our process for forecasting, ordering and receiving
   shipments may impact the
   ability to increase or decrease our level of
   supply in a timely manner; therefore, our supply of
   everolimus-eluting stent systems supplied to us by Abbott may not align with
   customer demand, which could have an adverse effect on our operating results. At present, we
   believe that our supply of
   everolimus-eluting stent systems from Abbott and our current launch plans for our
   next-generation internally-manufactured everolimus-eluting stent system is sufficient to meet
   customer demand. Our supply agreement with Abbott for
   everolimus-eluting  stent systems extends through the
   middle of the fourth quarter of 2009 in Europe, and is currently being reviewed by the European
   Commission for possible extension; and through
    the end of the second quarter of 2012 in the U.S.
   and Japan. We expect to launch our next-generation, internally-manufactured everolimus-eluting
       coronary stent system, the PROMUS&amp;#174; Element&amp;#8482; stent system, in our Europe/Middle East/Africa (EMEA)
   region and certain Inter-Continental countries in the fourth quarter of 2009 and in the U.S. and
       Japan in mid-2012.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition, the price we pay for our supply of everolimus-eluting stent systems from  Abbott is determined by contracts
       with Abbott and is based, in part, on previously fixed estimates of Abbott&amp;#8217;s manufacturing costs
       for everolimus-eluting stent systems and third-party reports of our average selling price of these  stent
       systems. Amounts paid pursuant to this pricing arrangement are subject to a retroactive adjustment
       at pre-determined intervals based on Abbott&amp;#8217;s actual costs to manufacture these stent systems for
       us and our average selling price of everolimus-eluting stent systems
       supplied to us by Abbott. During 2009, we may make a payment to or receive payment from Abbott based on the differences between their actual manufacturing costs and the contractually
       stipulated manufacturing costs, and differences between our actual average selling price and
       third-party reports of our average selling price, in each case, with respect to our purchases of
       PROMUS&amp;#174; stent systems from Abbott during 2006, 2007 and a portion of 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Property, plant and equipment, net&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Property, plant and equipment
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,186&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3,110&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less: accumulated depreciation
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,467&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,382&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,719&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,728&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Depreciation expense was $78&amp;#160;million for the second quarter of 2009, $79&amp;#160;million for the second
       quarter of 2008, $152&amp;#160;million for the first half of 2009, and $159&amp;#160;million for the first half of
       2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Other intangible assets, net&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Core technology
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,855&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6,855&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other intangible assets
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,384&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,381&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9,239&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9,236&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Less: accumulated amortization
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,258&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,992&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;6,981&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7,244&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;During the second quarter of 2009, due to lower than anticipated market penetration of one of our
       Urology technology offerings, we lowered our sales forecasts associated with the product. As a
       result, we tested the related intangible assets for impairment in accordance with the provisions of
       FASB Statement No.&amp;#160;144, &lt;i&gt;Accounting for the Impairment or Disposal of Long-Lived Assets, &lt;/i&gt;and
       recorded a $10&amp;#160;million charge to write off the balance of these intangible assets as of June&amp;#160;30,
       2009. We have recorded these amounts in the intangible asset impairment charges caption in our
       accompanying unaudited condensed consolidated financial statements, and these amounts have been
       excluded from the determination of segment income considered by management.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Accrued Expenses&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Legal reserves
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;863&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;924&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Acquisition-related obligations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;520&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Payroll and related liabilities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;392&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;438&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Restructuring liabilities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;50&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;42&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accrual for program termination
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;693&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;688&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,021&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,612&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In the second quarter of 2009, we cancelled one of our internal research and development (R&amp;#038;D)
   programs in order to focus on those with a higher likelihood of success. As a result, we recorded a
       pre-tax loss of $16&amp;#160;million, in accordance with FASB Statement No.&amp;#160;146, &lt;i&gt;Accounting for Costs
       Associated with Exit or Disposal Activities, &lt;/i&gt;associated with future payments that we
       believe we remain contractually obligated to make. This obligation is included in accrued expenses
       within our accompanying unaudited condensed consolidated financial statements as of June&amp;#160;30, 2009,
       and presented above.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Other Long-term Liabilities&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Legal reserves
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;404&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;165&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accrued income taxes
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,158&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,100&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other long-term liabilities
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;382&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;462&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,944&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,727&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;u&gt;Accrued Warranties&lt;/u&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Changes in our product warranty accrual during the first half of 2009 consisted of the following
   (in millions):
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="88%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance as of December&amp;#160;31, 2008&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;62&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Provision
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;10&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Settlements/ reversals
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(18&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance as of June&amp;#160;30, 2009&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;54&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</bsx:SupplementalBalanceSheetInformationTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DebtDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:DebtDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE D &amp;#8212; BORROWINGS AND CREDIT ARRANGEMENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We had total debt of $6.250&amp;#160;billion as of June&amp;#160;30, 2009 at an average interest rate of 5.51
   percent, as compared to total debt of $6.745&amp;#160;billion as of December&amp;#160;31, 2008 at an average interest
   rate of 5.65&amp;#160;percent. The debt maturity schedule for the significant components of our debt
   obligations as of June&amp;#160;30, 2009 is as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="23" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Payments due by Period&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Thereafter&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td style="border-bottom: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Term loan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;325&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,325&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Abbott Laboratories loan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;900&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;900&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Senior notes
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;850&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,200&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3,050&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;325&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3,750&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,200&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;6,275&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 8pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom" style="font-size: 1pt"&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="2%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td align="left" valign="top"&gt;Note:&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="top"&gt;The table above does not include discounts associated
   with our Abbott loan and senior notes, or amounts
   related to certain interest rate swaps that were used to
   hedge the fair value of certain of our senior notes.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In July&amp;#160;2009, we made a prepayment of $225&amp;#160;million towards our term loan. As a result, our
       next debt maturity is $100&amp;#160;million due in April&amp;#160;2010.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In February&amp;#160;2009, we amended our term loan and revolving credit facility agreement to increase
       flexibility under our financial covenants. The amendment provides for an exclusion from the
       calculation of consolidated EBITDA, as defined by the amended agreement, through the credit
       agreement maturity in April&amp;#160;2011, of up to $346&amp;#160;million in restructuring charges to support our
       Plant Network Optimization and other expense reduction initiatives, described in &lt;i&gt;Note F -
   Restructuring-related Activities&lt;/i&gt;; an exclusion for any litigation-related charges and credits until
       such items are paid or received; and an exclusion of up to $1.137&amp;#160;billion of any cash payments for
       litigation settlements or damage awards (net of any litigation payments received), and all cash
       payments (net of cash receipts) related to amounts that were recorded in the financial statements
       before January&amp;#160;1, 2009. At the same time, we prepaid $500&amp;#160;million of our term loan. In addition,
       the agreement provides for an increase in interest rates on our term loan borrowings from LIBOR
       plus 1.00&amp;#160;percent to LIBOR plus 1.75&amp;#160;percent at current credit ratings. Further, the interest rate
       on unused facilities increased from 0.175&amp;#160;percent to 0.500&amp;#160;percent.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In connection with the amendment of our term loan and revolving credit facility, we reduced
       availability under our credit facility by $250&amp;#160;million to $1.750&amp;#160;billion. Further reducing our
       borrowing capacity, in 2008, we issued a $717&amp;#160;million surety bond backed by a $702&amp;#160;million letter
       of credit and $15&amp;#160;million of cash to secure a damage award related to the Johnson &amp;#038; Johnson patent
       infringement case pending appeal, described in &lt;i&gt;Note L &amp;#8212; Commitments and Contingencies. &lt;/i&gt;We also
       maintain a $350&amp;#160;million credit and security facility secured by our U.S. trade receivables. Use of
       the borrowings is unrestricted. Borrowing availability under this facility changes based upon the
       amount of eligible receivables, concentration of eligible receivables and other factors. During the
       third quarter of 2009, we extended the maturity of this facility to August&amp;#160;2010. There were no
       amounts borrowed under this facility as of June&amp;#160;30, 2009 or December&amp;#160;31, 2008. Further, we have
       uncommitted credit facilities with two commercial Japanese banks that provide for borrowings and
       promissory notes discounting of up to 18.5&amp;#160;billion Japanese yen (translated to approximately
   $192&amp;#160;million as of June&amp;#160;30, 2009 and $205&amp;#160;million as of December&amp;#160;31, 2008). We discounted notes
       receivable of $188&amp;#160;million as of June&amp;#160;30, 2009 and $190&amp;#160;million as of December&amp;#160;31, 2008. Discounted
       notes receivable are excluded from accounts receivable in the accompanying unaudited condensed
       consolidated balance sheets.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Our term loan and revolving credit facility agreement requires that we maintain certain financial
       covenants, as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="55%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="76%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="7%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;
       &lt;td width="7%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Covenant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Actual as of&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Requirement&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30, 2009&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Maximum leverage ratio (1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="top"&gt;4.0 to 1.0
   &lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="top"&gt;2.9 to 1.0&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td valign="top"&gt;
   &lt;div style="margin-left:0px; text-indent:-0px"&gt;Minimum interest coverage ratio (2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="top"&gt;3.0 to 1.0
   &lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left" valign="top"&gt;5.2 to 1.0&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Ratio of total debt to EBITDA, as defined by the
   agreement, as amended, for the preceding four fiscal
   quarters. The maximum permitted leverage ratio steps down
   to 3.5 to 1.0 on September&amp;#160;30, 2009.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(2)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Ratio of EBITDA, as defined by the agreement, as amended, to interest
   expense for the preceding four consecutive fiscal quarters.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;As of June&amp;#160;30, 2009, we were in compliance with the required covenants. Our inability to
       maintain these covenants could require us to seek to renegotiate the terms of our credit facilities
       or seek waivers from compliance with these covenants, both of which could result in additional
       borrowing costs. Further, there can be no assurance that our lenders would grant such waivers.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:DebtDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:BusinessCombinationDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE E &amp;#8212; ACQUISITIONS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;i&gt;Purchased Research and Development&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Our policy is to record certain costs associated with strategic alliances as purchased research and
   development. Our adoption of FASB Statement No.&amp;#160;141(R), &lt;i&gt;Business Combinations, &lt;/i&gt;as of January&amp;#160;1,
   2009, did not change this policy with respect to asset purchases. In accordance with this policy,
   we recorded purchased research and development charges of $17&amp;#160;million in the second quarter and
   first half of 2009, and $13&amp;#160;million in the first half of 2008, associated with entering certain
   licensing and development arrangements. Since the technology purchases did not involve the
   transfer of processes or outputs as defined by Statement No.&amp;#160;141(R), the transaction did not
   qualify as a business combination. We did not consummate any material business combinations in the
   first half of 2009. For any future business combinations that we enter, we will recognize purchased
   research and development as an intangible asset, in accordance with Statement No.&amp;#160;141(R). In the
   second quarter of 2008, we completed the acquisition of 100&amp;#160;percent of the fully diluted equity of
   CryoCor, Inc., and paid a cash purchase price of $21&amp;#160;million. In connection with the acquisition,
   we recorded pre-tax purchased research and development charges of $16&amp;#160;million.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Payments Related to Prior Period Acquisitions&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Certain of our acquisitions involve the payment of contingent consideration. Payment of the
   additional consideration is generally contingent on the acquired company reaching certain
   performance milestones, including attaining specified revenue levels, achieving product development
   targets or obtaining regulatory approvals. In August&amp;#160;2007, we entered an agreement to amend our
   2004 merger agreement with the principal former shareholders of Advanced Bionics Corporation.
   Previously, we were obligated to pay future consideration contingent primarily on the achievement
   of future performance milestones. The amended agreement provided a new schedule of consolidated,
   fixed payments, consisting of $650&amp;#160;million that was paid in 2008, and a final $500&amp;#160;million payment,
   which we made during the first quarter of 2009. During the first half of 2009, including the $500
   million payment to the former shareholders of Advanced Bionics, we made total payments of $517
   million related to prior period acquisitions. As of June&amp;#160;30, 2009, the estimated maximum potential
   amount of future contingent consideration (undiscounted)&amp;#160;that we could be required to make
   associated with our prior acquisitions is approximately $730&amp;#160;million. The milestones associated
   with the contingent consideration must be reached in certain future periods ranging from 2009
   through 2025. The estimated cumulative specified revenue level associated with these maximum future
   contingent payments is approximately $2.8&amp;#160;billion.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE F &amp;#8212; RESTRUCTURING-RELATED ACTIVITIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In October&amp;#160;2007, our Board of Directors approved, and we committed to, an expense and head count
   reduction plan (the 2007 Restructuring plan), which resulted in the elimination of approximately
   2,300 positions worldwide. We are providing affected employees with severance packages,
   outplacement services and other appropriate assistance and support. The plan is intended to bring
   expenses in line with revenues as part of our initiatives to enhance short- and long-term
   shareholder value. Key activities under the plan include the restructuring of several businesses,
   corporate functions and product franchises in order to better utilize resources, strengthen
   competitive positions, and create a more simplified and efficient business model; the elimination,
   suspension or reduction of spending on certain R&amp;#038;D projects; and the transfer of certain production
   lines among facilities. We initiated these activities in the fourth quarter of 2007 and expect to
   be
   substantially complete in 2010.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We expect that the execution of this plan will result in total pre-tax expenses of approximately
   $425&amp;#160;million to $450&amp;#160;million. We are recording a portion of these expenses as restructuring
   charges and the remaining portion through other lines within our consolidated statements of
   operations. We expect the plan to result in cash payments of approximately $390&amp;#160;million to $405
   million. The following provides a summary of our expected total costs associated with the plan by
   major type of cost:
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="88%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="7%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Total estimated amount expected to&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Type of cost&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;be incurred&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Termination benefits
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$215 million to $225 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Fixed asset write-offs
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$20 million to $25 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other (1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$70 million to $75 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Retention incentives
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$70 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accelerated depreciation
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$15 million to $20 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Transfer costs (2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$35 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&lt;b&gt;$425 million to $450 million&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Consists primarily of consulting fees, contractual cancellations, relocation costs and other costs.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(2)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Consists primarily of costs to transfer product lines among facilities, including costs of transfer
   teams, freight and product line validations.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition, in January&amp;#160;2009, our Board of Directors approved, and we committed to, a Plant
       Network Optimization plan, which is intended to simplify our manufacturing plant structure by
       transferring certain production lines among facilities and by closing certain other facilities. The
       plan is a complement to our 2007 Restructuring plan, and is intended to improve overall gross
       profit margins. Activities under the Plant Network Optimization plan were initiated in the first
       quarter of 2009 and are expected to be substantially complete by the end of 2011. We estimate that
       the execution of this plan will result in total pre-tax charges of approximately $135&amp;#160;million to
   $150&amp;#160;million, and that approximately $120&amp;#160;million to $130&amp;#160;million of these charges will result in
       future cash outlays. The following provides a summary of our estimates of costs associated with
       the Plant Network Optimization plan by major type of cost:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="88%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="7%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Total estimated amount expected to&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Type of cost&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;be incurred&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Termination benefits
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$45 million to $50 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accelerated depreciation
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$15 million to $20 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Transfer costs (1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;$75 million to $80 million&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top"&gt;&lt;b&gt;$135 million to $150 million&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="top" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 8pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;
   &lt;div align="justify"&gt;Consists primarily of costs to transfer product lines among
   facilities, including costs of transfer teams, freight and product
   line validations.
   &lt;/div&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We recorded restructuring charges of $13&amp;#160;million in the second quarter of 2009 and $10&amp;#160;million
       in the second quarter of 2008. In addition, we recorded expenses within other lines of our
       unaudited condensed
       consolidated statements of operations related to our restructuring initiatives of $17&amp;#160;million in
       the second quarter of 2009 and $11&amp;#160;million in the second quarter of 2008. The following presents
       these costs by major type and line item within our accompanying unaudited condensed consolidated
       statements of operations:
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;b&gt;&lt;u&gt;Three
       Months Ended June&amp;#160;30, 2009&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt; Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;13&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" STYLE="FONT-SIZE:8PT"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Cost of products sold
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Selling, general and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;17&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;30&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;u&gt;Three
       Months Ended June&amp;#160;30, 2008&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt; Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;10&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;10&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" STYLE="FONT-SIZE:8PT"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Cost of products sold
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Selling, general and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;10&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;11&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;10&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;10&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 16pt"&gt;Restructuring and restructuring-related costs recorded in the second quarter of 2009 by plan were
       as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2007 Restructuring plan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;24&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Plant Network Optimization plan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;7&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;30&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 16pt"&gt;We recorded restructuring charges of $36&amp;#160;million in the first half of 2009 and $39&amp;#160;million in the
       first half of 2008. In addition, we recorded expenses within other lines of our unaudited
       condensed consolidated statements of operations related to our restructuring initiatives of $30
   million in the first half of 2009 and $26&amp;#160;million in the first half of 2008. The following presents
       these costs by major type and line item within our accompanying unaudited condensed consolidated
       statements of operations:
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;u&gt;Six
       Months Ended June&amp;#160;30, 2009&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt; Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;36&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" STYLE="FONT-SIZE:8PT"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Cost of products sold
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;22&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Selling, general and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;11&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;30&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;11&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;66&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;u&gt;Six
       Months Ended June&amp;#160;30, 2008&lt;/u&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer &lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring charges&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;20&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;19&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;39&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" STYLE="FONT-SIZE:8PT"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related expenses:&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Cost of products sold
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Selling, general and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;5&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;26&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;20&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;5&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;19&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;65&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Restructuring and restructuring-related costs recorded in the first half of 2009 by plan were as
       follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="23%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="4%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Retention&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Accelerated&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Transfer&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Fixed Asset&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Incentives&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 0px solid #000000"&gt;&lt;b&gt;Depreciation&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Costs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Write-offs&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="29" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;2007 Restructuring plan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;11&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;10&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;41&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td nowrap="nowrap"&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Plant Network Optimization plan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;25&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;21&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;11&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;66&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="27" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Termination benefits represent amounts incurred pursuant to our on-going benefit arrangements and
       amounts for &amp;#8220;one-time&amp;#8221; involuntary termination benefits, and have been recorded in accordance with
       FASB Statement No.&amp;#160;112, &lt;i&gt;Employer&amp;#8217;s Accounting for Postemployment Benefits &lt;/i&gt;and FASB Statement No.
   146, &lt;i&gt;Accounting for Costs Associated with Exit or Disposal Activities. &lt;/i&gt;We expect to record the
       additional termination benefits throughout the remainder of 2009 and 2010 when we identify with
       more specificity the job classifications, functions and locations of the remaining head count to be
       eliminated. Retention incentives represent cash incentives, which are being recorded over the
       future service period during which eligible employees must remain employed with us in order to
       retain the payment. Other restructuring costs, which represent primarily consulting fees, are
       being recognized and measured at their fair value in the period in which the liability is incurred
       in accordance with Statement No.&amp;#160;146. Accelerated depreciation is being recorded over the new
       remaining useful life of the related assets, and production line transfer costs are being recorded
       as incurred.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We have incurred cumulative restructuring charges of $290&amp;#160;million and restructuring-related costs
       of $93&amp;#160;million since we committed to each plan. The following presents these costs by major type
       and by plan:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2007&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Plant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Restructuring&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Network&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Plan&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Optimization&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="13" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Termination benefits
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;196&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;213&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Fixed asset write-offs
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Other
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Total restructuring charges&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;273&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;17&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;290&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Retention incentives
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;59&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;59&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Accelerated depreciation
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;15&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Transfer costs
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;14&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;19&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
   &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Restructuring-related
   expenses&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;85&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;8&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;93&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;358&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;25&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;383&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In the second quarter of 2009, we made cash payments of approximately $20&amp;#160;million associated with
       restructuring initiatives pursuant to our 2007 Restructuring plan, which related to termination
       benefits and retention incentives, production line transfer costs and other restructuring
       costs. We have made cumulative cash payments of approximately $270&amp;#160;million since we committed to
       the 2007 Restructuring plan. These payments were made using cash generated from our operations. We
       expect to record the remaining costs associated with the 2007 Restructuring plan during the
       remainder of 2009 and make future cash payments throughout the remainder of 2009 and into 2010
   using cash generated from operations. In the second quarter of 2009, we made cash payments of
       approximately $3&amp;#160;million associated with our Plant Network Optimization plan, which related to
       production line transfer costs. We have made cumulative cash payments of $5&amp;#160;million since
       committing to the Plant Network Optimization plan. These payments were made using cash generated
       from our operations. We expect to record the remaining costs associated with the Plant Network
       Optimization plan through 2011, and make future cash payments through 2011 using cash generated
       from operations.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following is a rollforward of the liability associated with our restructuring initiatives,
       since the inception of the respective plan, which is reported as a component of accrued expenses
       included in our accompanying unaudited condensed consolidated balance sheets.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="40%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Plant&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Network&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="10" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2007 Restructuring Plan&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Optimization&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Termination&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Subtotal&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td style="border-bottom: 1px solid #000000" nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Benefits&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td style="border-bottom: 1px solid #000000" nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
       &lt;td style="border-top: 0px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td STYLE="border-top:1px solid black"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Charges
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;158&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;10&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;168&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;168&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash payments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(23&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(31&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(31&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance as of December&amp;#160;31, 2007&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;135&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;137&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;137&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Charges
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;34&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;34&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;68&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;68&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash payments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(128&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(35&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(163&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(163&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance as of December&amp;#160;31, 2008&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;41&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;42&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;42&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Charges
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;16&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;33&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash payments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(13&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(12&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(25&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(25&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000; border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Balance as of June&amp;#160;30, 2009&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;32&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;33&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;17&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;50&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="11" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000; border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000; border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition to the amounts in the rollforward above, we have incurred cumulative charges of $106
   million associated with retention incentives, asset write-offs, accelerated depreciation and
       transfer costs pursuant to our 2007 Restructuring plan, and made cumulative cash payments of
       approximately $38&amp;#160;million associated with retention incentives and $14&amp;#160;million associated with
       transfer costs. We have also incurred cumulative charges of $9&amp;#160;million associated with accelerated
       depreciation and transfer costs pursuant to our Plant Network Optimization plan and made cumulative
       cash payments of $5&amp;#160;million.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE G &amp;#8212; DIVESTITURES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;During 2007, we determined that our Auditory, Vascular Surgery, Cardiac Surgery, Venous Access and
   Fluid Management businesses were no longer strategic to our on-going operations. We completed the
   sale of these businesses in the first quarter of 2008, receiving pre-tax proceeds of approximately
   $1.3&amp;#160;billion.
    During the first quarter of 2008, we recorded a $250 million gain
   in connection with the sale of our Fluid Management and Venous Access businesses and
   our TriVascular Endovascular Aortic Repair (EVAR) program. In February 2008, we
   completed the sale of our Fluid Management and Venous Access businesses to Navylist
   Medical (affiliated with Avista Capital Partners) for net cash proceeds of
   approximately $400 million. We recorded a pre-tax gain of $234 million ($161 million
   after-tax) during the first quarter of 2008 associated with this transaction. We
   acquired the Fluid Management business as part of our acquisition of Schneider
   Worldwide in 1998. The Venous Access business was previously a component of our former
   Oncology business. In March 2008, we sold our EVAR program obtained in connection
   with our 2005 acquisition of TriVascular, Inc. for $30 million in cash. We discontinued
   our EVAR program in 2006. In connection with the sale, we recorded a pre-tax gain
   of $16 million ($36 million after-tax) during 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;During 2007, we announced our intent to monetize those investments in our portfolio determined to
   be non-strategic. During 2008, we entered transactions to sell the majority of our investments in,
   and notes receivable
   from, certain publicly traded and privately held entities, and received pre-tax proceeds for
   investments sold of $149&amp;#160;million. During the first quarter of 2009, we substantially completed the
   sale of our non-strategic investments, and received additional proceeds and collections of notes
   receivable of approximately $50&amp;#160;million. We recognized a net gain of $3&amp;#160;million associated with
   these transactions in the first half of 2009, and a net loss of $96&amp;#160;million during the first half
   of 2008.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <bsx:ComprehensiveIncomeTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 8 - bsx:ComprehensiveIncomeTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE H &amp;#8212; COMPREHENSIVE INCOME&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following table provides a summary of our comprehensive income:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="60%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000" &gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net income
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;158&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;98&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;145&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;420&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Foreign currency translation adjustment
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;26&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;30&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net change in unrealized gains and losses on
   derivative
   financial instruments, &lt;br /&gt;
   net of tax
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(66&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;65&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;9&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(28&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Net change in unrealized gains or losses on equity
   investments, net of tax
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Other
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Comprehensive income&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;118&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;182&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;175&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;412&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</bsx:ComprehensiveIncomeTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <bsx:WeightedAverageSharesOutstandingTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 9 - bsx:WeightedAverageSharesOutstandingTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE I
   &amp;#8212;  WEIGHTED-AVERAGE SHARES OUTSTANDING&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following is a reconciliation of weighted-average shares outstanding for basic and diluted
   earnings per share computations:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="9" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="3" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Weighted average shares outstanding &amp;#8212; basic
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,506.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,497.6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,505.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,495.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net effect of common stock equivalents
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6.8&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Weighted
   average shares outstanding &amp;#8212; assuming dilution&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,514.5&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,505.2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,511.6&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;1,502.6&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Weighted-average shares outstanding, assuming dilution, excludes the impact of 51&amp;#160;million stock
   options for the second quarter of 2009, 41&amp;#160;million for the second quarter of 2008, 58&amp;#160;million for
   the first half of 2009, and 49&amp;#160;million for the first half of 2008, due to the exercise prices of
   these stock options being greater than the average market price of our common stock during those
   periods.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We issued approximately 1.0&amp;#160;million shares of our common stock in the second quarter of 2009, 3.3
   million in the second quarter of 2008, 5.6&amp;#160;million during the first half of 2009, and 7.5&amp;#160;million
   during the first half of 2008 following the exercise or vesting of the underlying stock options or
   deferred stock units, or purchase under our employee stock purchase plan.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</bsx:WeightedAverageSharesOutstandingTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <bsx:StockBasedCompensationTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 10 - bsx:StockBasedCompensationTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE J &amp;#8212; STOCK-BASED COMPENSATION&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following presents the impact of stock-based compensation expense on our unaudited condensed
   consolidated statements of operations:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td colspan="9" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cost of products sold
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Selling, general and administrative expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;49&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;49&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Research and development expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;17&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;14&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;33&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;34&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;78&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;75&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Income tax benefit
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(10&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(25&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(23&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;23&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;23&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;53&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;52&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Impact on net income per common share &amp;#8212; basic
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.02&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.02&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.04&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.03&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Impact on net income per common share &amp;#8212; assuming dilution
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.02&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.02&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.04&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;(0.03&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</bsx:StockBasedCompensationTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;NOTE K &amp;#8212; INCOME TAXES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The following table provides a summary of our reported tax rate:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="75%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="64%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Three  Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Point&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Increase (Decrease)&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Reported tax rate
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;12.2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;10.2&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Impact of certain charges*
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6.5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;18.1&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(11.6&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;Point&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Increase (Decrease)&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Reported tax rate
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(74.7&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;25.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(100.0&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Impact of certain charges*
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;94.5&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3.3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)%&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;97.8&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;%&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr&gt;
       &lt;td width="3%"&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&lt;/td&gt;
       &lt;td width="96"&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;*&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;These charges are taxed at different rates than our effective tax rate.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The change in our reported tax rate for the second quarter and first half of 2009, as compared
   to the same periods in 2008, relates primarily to the impact of certain charges that are taxed at
   different rates than our effective tax rate. In 2009, these charges included intangible asset
   impairment charges, purchased research and development charges, restructuring- and
   litigation-related charges, and a favorable tax ruling on a divestiture-related gain recognized in
   a prior period. Our reported tax rate was also affected by discrete items, associated primarily
   with resolutions of uncertain tax positions and a favorable adjustment as a result of a state law
   change, resulting in tax benefits of $13&amp;#160;million for the second quarter of 2009 and $87&amp;#160;million for
   the first half of 2009. In 2008, these charges included purchased research and development
   charges, a gain on the divestiture of certain non-strategic businesses, restructuring-related
   charges, and discrete tax items associated with the resolution of various tax matters.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;As of January&amp;#160;1, 2009, we adopted FASB Statement No.&amp;#160;141(R), &lt;i&gt;Business Combinations, &lt;/i&gt;which requires
   that we recognize changes in acquired income tax uncertainties (applied to acquisitions before and
   after the adoption date) as income tax expense or benefit. As of June&amp;#160;30, 2009, we had $1.082
   billion of gross unrecognized tax benefits, $959&amp;#160;million of which, if recognized, would affect our
   effective tax rate. As of December&amp;#160;31, 2008, we had $1.107&amp;#160;billion of gross unrecognized tax
   benefits, $978&amp;#160;million of which, if recognized, would affect our effective tax rate. The net
   reduction in our unrecognized tax benefits is attributable primarily to the resolution of certain
   unrecognized tax positions related to audit settlements of $59&amp;#160;million in the first half of 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We recognize interest and penalties related to income taxes as a component of income tax expense.
   We recognized income tax related interest and penalties of $8&amp;#160;million in the second quarter of
   2009, $13&amp;#160;million in the second quarter of 2008, $20&amp;#160;million in the first half of 2009 and $11
   million in the first half of 2008, including a net release in the first quarter. We had $296
   million accrued for gross interest and penalties as of June&amp;#160;30, 2009 and $268&amp;#160;million as of
   December&amp;#160;31, 2008.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We are subject to U.S. federal income tax as well as income tax of multiple state and foreign
   jurisdictions. We have concluded all U.S. federal income tax matters through 2000 and
   substantially all material state, local, and foreign income tax matters through 2001. During the
   first half of 2009, we resolved various federal and foreign jurisdictions matters.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In the second quarter of 2009, we received the Revenue Agent&amp;#8217;s Report for our federal tax
   examination covering years 2004 and 2005, which contained proposed adjustments, related primarily
   to transfer pricing
   and transaction-related issues. We agreed on certain adjustments and made
       associated payments of $64&amp;#160;million, inclusive of interest, in the second quarter of 2009. We
       disagree with certain positions contained in the Report and intend to contest these positions
       through applicable IRS and judicial procedures, as appropriate. We also continue to disagree with
       and contest the significant proposed adjustment, related primarily to the allocation of income
       between our U.S. and foreign affiliates, contained in the Revenue Agent&amp;#8217;s Report for Guidant
       Corporation&amp;#8217;s federal tax examination covering years 2001 through 2003, which we received in 2008.
   Although the final resolution associated with these matters is uncertain, we believe that our
       income tax reserves are adequate and that the resolution will not have a material impact on our
       financial condition or results of operations.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;It is reasonably possible that within the next 12&amp;#160;months we will resolve multiple issues including
       transfer pricing, research and development tax credit and various transactional related issues,
       with foreign, federal and state taxing authorities, in which case we could record a reduction in
       our balance of unrecognized tax benefits of up to approximately $82&amp;#160;million.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 12 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE L &amp;#8212; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;The medical device market in which we primarily participate is largely technology driven. Physician
   customers, particularly in interventional cardiology, have historically moved quickly to new
   products and new technologies. As a result, intellectual property rights, particularly patents and
   trade secrets, play a significant role in product development and differentiation. However,
   intellectual property litigation to defend or create market advantage is inherently complex and
   unpredictable. Furthermore, appellate courts frequently overturn lower court patent decisions.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition, competing parties frequently file multiple suits to leverage patent portfolios across
   product lines, technologies and geographies and to balance risk and exposure between the parties.
   In some cases, several competitors are parties in the same proceeding, or in a series of related
   proceedings, or litigate multiple features of a single class of devices. These forces frequently
   drive settlement not only of individual cases, but also of a series of pending and potentially
   related and unrelated cases. In addition, although monetary and injunctive relief is typically
   sought, remedies and restitution are generally not determined until the
   conclusion of the proceedings and are frequently modified on appeal. Accordingly, the outcomes of
   individual cases are difficult to time, predict or quantify and are often dependent upon the
   outcomes of other cases in other geographies.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Several third parties have asserted that our current and former stent systems infringe patents
   owned or licensed by them. We have similarly asserted that stent systems or other products sold by
   our competitors infringe patents owned or licensed by us. Adverse outcomes in one or more of the
   proceedings against us could limit our ability to sell certain stent products in certain
   jurisdictions, or reduce our operating margin on the sale of these products and could have a
   material adverse effect on our financial position, results of operations or liquidity.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In particular, we are engaged in significant patent litigation with Johnson &amp;#038; Johnson relating to
   stent systems, balloon catheters and stent delivery systems. We have each asserted that products
   of the other infringe patents owned or exclusively licensed by each of us. Adverse outcomes in one
   or more of these matters could have a material adverse effect on our ability to sell certain
   products and on our operating margins, financial position, results of operation or liquidity.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In the normal course of business, product liability and securities claims are asserted against us.
   Similar claims may be asserted against us in the future related to events not known to management
   at the present time. We are substantially self-insured with respect to product liability claims,
   and maintain an insurance policy providing limited coverage against securities claims. The absence
   of significant third-party insurance coverage increases our potential exposure to unanticipated
   claims or adverse decisions. Product liability claims, product recalls, securities litigation, and
   other legal proceedings in the future, regardless of their outcome, could have a material adverse
   effect on our financial position, results of operations and liquidity.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In addition, the medical device industry is the subject of numerous governmental investigations
       often involving marketing and other business practices. These investigations could result in the
       commencement of civil and criminal proceedings, substantial fines, penalties and administrative
       remedies, divert the attention of our management and have an adverse effect on our financial
       position, results of operations and liquidity.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We record losses for claims in excess of the limits of purchased insurance in earnings at the time
       and to the extent they are probable and estimable. In accordance with FASB Statement No.&amp;#160;5,
   &lt;i&gt;Accounting for Contingencies, &lt;/i&gt;we accrue anticipated costs of settlement and damages and, under
       certain conditions, costs of defense, based on historical experience or to the extent specific
       losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate
       of a probable loss is a range and no amount within the range is more likely, we accrue the minimum
       amount of the range.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Our accrual for legal matters that are probable and estimable was $1.267&amp;#160;billion as of June&amp;#160;30,
       2009 and $1.089&amp;#160;billion as of December&amp;#160;31, 2008, and includes estimated costs of settlement,
       damages and defense. The increase in our accrual is due primarily to first quarter charges of $237
   million as a result of a ruling in a patent infringement case brought against us by Johnson &amp;#038;
       Johnson, and $50&amp;#160;million related to the settlement of a patent infringement case brought against us
       by Bruce Saffran, M.D., Ph.D, described below. Partially offsetting this increase was a decrease of
       approximately $100&amp;#160;million attributable to litigation-related payments made during the first half
       of the year. We continue to assess certain litigation and claims to determine the amounts that
       management believes will be paid as a result of such claims and litigation and, therefore,
       additional losses may be accrued in the future, which could materially adversely impact our
       operating results, cash flows and our ability to comply with our debt covenants.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In management&amp;#8217;s opinion, we are not currently involved in any legal proceedings other than those
       specifically identified below or as disclosed in our 2008 Annual Report on Form 10-K, which,
       individually or in the aggregate, could have a material effect on our financial condition,
       operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a
       range of loss associated with any individual material legal proceeding cannot be estimated. Except
       as disclosed below, there have been no material developments with regard to the litigation or other
       proceedings disclosed in our 2008 Annual Report on Form
       10-K.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Litigation with Johnson &amp;#038; Johnson&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On October&amp;#160;22, 1997, Cordis Corporation, a subsidiary of Johnson &amp;#038; Johnson, filed a suit for patent
       infringement against us and Boston Scientific Scimed, Inc. (f/k/a SCIMED Life Systems, Inc.), our
       wholly owned subsidiary, alleging that the importation and use of the NIR&amp;#174; stent infringes two
       patents owned by Cordis. On April&amp;#160;13, 1998, Cordis filed another suit for patent infringement
       against Boston Scientific Scimed and us, alleging that our NIR&amp;#174; stent infringes two additional
       patents owned by Cordis. The suits were filed in the U.S. District Court for the District of
       Delaware seeking monetary damages, injunctive relief and that the patents be adjudged valid,
       enforceable and infringed. A jury trial on both actions found that the NIR&amp;#174; stent infringed one
       claim of one Cordis patent and awarded damages of approximately $324&amp;#160;million to Cordis. On May&amp;#160;16,
       2002, the Court set aside the verdict of infringement, requiring a new trial. On March&amp;#160;24, 2005, in
       a second trial, a jury found that a single claim of a Cordis patent was valid and infringed. Our
       appeals of the infringement decision were denied. On September&amp;#160;30, 2008, the District Court entered
       final judgment against us and awarded Cordis $702&amp;#160;million in damages and interest. As a result of
       the Court&amp;#8217;s ruling, we increased our accrual for litigation-related matters by $334&amp;#160;million in the
       third quarter of 2008. This accrual is in addition to $368&amp;#160;million of previously established
       accruals related to this matter. On October&amp;#160;10, 2008, we appealed the damage award and the oral argument
       was held on June&amp;#160;5, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On February&amp;#160;14, 2002, we, and certain of our subsidiaries, filed suit for patent infringement
       against Johnson &amp;#038; Johnson and Cordis alleging that certain balloon catheters and stent delivery
       systems sold by Johnson &amp;#038; Johnson and Cordis infringe five U.S. patents owned by us. The complaint
       was filed in the U.S. District Court
   for the Northern District of California seeking monetary and
       injunctive relief. On October&amp;#160;15, 2002, Cordis filed a counterclaim alleging that certain balloon
       catheters and stent delivery systems sold by us infringe three U.S. patents owned by Cordis and
       seeking monetary and injunctive relief. On December&amp;#160;6, 2002, we filed an amended complaint alleging
       that two additional patents owned by us are infringed by the Cordis&amp;#8217; products. On October&amp;#160;31, 2007,
       a jury found that we infringe a patent of Cordis. The jury also found four of our patents invalid
       and infringed by Cordis. No damages were determined because the judge found that Cordis failed to
       submit evidence sufficient to enable a jury to make a damage assessment. On April&amp;#160;9, 2009, the
       District Court awarded Cordis a post judgment royalty on certain sales after November&amp;#160;2007. On July
       24, 2009, we appealed the decisions of the District Court and, on July&amp;#160;30, 2009, Cordis cross
       appealed.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On January&amp;#160;13, 2003, Cordis filed suit for patent infringement against Boston Scientific Scimed and
       us alleging that our Express 2&amp;#174; coronary stent infringes a U.S. patent owned by Cordis. The suit
       was filed in the U.S. District Court for the District of Delaware seeking monetary and injunctive
       relief. We filed a counterclaim alleging that certain Cordis products infringe a patent owned by
       us. On August&amp;#160;4, 2004, the Court granted a Cordis motion to add our Libert&amp;#233;&amp;#174; coronary stent and two
       additional patents to the complaint. On June&amp;#160;21, 2005, a jury found that our TAXUS&amp;#174; Express 2&amp;#174;,
       Express 2&amp;#174;, Express&amp;#174; Biliary, and Libert&amp;#233;&amp;#174; stents infringe a Johnson &amp;#038; Johnson patent and that the
       Libert&amp;#233;&amp;#174; stent infringes a second Johnson &amp;#038; Johnson patent. With respect to our counterclaim, a
       jury found on July&amp;#160;1, 2005, that Johnson &amp;#038; Johnson&amp;#8217;s Cypher&amp;#174;, Bx Velocity&amp;#174;, Bx Sonic&amp;#174; and Genesis&amp;#8482;
       stents infringe our patent. On March&amp;#160;31, 2009, the Court of Appeals upheld the District Court&amp;#8217;s
       decision that Johnson &amp;#038; Johnson&amp;#8217;s Cypher&amp;#174;, Bx Velocity&amp;#174;, Bx Sonic&amp;#174; and Genesis&amp;#8482; stent systems
       infringe our patent and that the patent is valid. The Court of Appeals instructed the District
       Court to dismiss with prejudice the infringement claims against our TAXUS Libert&amp;#233;&amp;#174; stent. The Court
       of Appeals affirmed the District Court&amp;#8217;s ruling that our TAXUS&amp;#174; Express 2&amp;#174;, Express 2&amp;#174;, Express&amp;#174;
       Biliary, and Libert&amp;#233;&amp;#174; stents infringe one Johnson &amp;#038; Johnson patent and that the patent is valid.
   The Court of Appeals also affirmed that our Libert&amp;#233;&amp;#174; stent infringes a second Johnson &amp;#038; Johnson
       patent and that the patent is valid. In conjunction with the March&amp;#160;31, 2009 Court of Appeals
       decision, we recorded a litigation-related charge of $237&amp;#160;million during the first quarter of
       2009. This amount represents an estimate of the low end of the range of potential outcomes related
       to this matter. The range is subject to substantial estimation, including attempting to determine
       the possible future findings of a jury. As such, the high end of the range cannot be reasonably
       estimated at this time. Both parties filed a request for a rehearing and a rehearing en banc with
       the Court of Appeals, and on June&amp;#160;26, 2009, the Court of Appeals denied both petitions. Damages
       will be
       determined in a future court proceeding.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On March&amp;#160;13, 2003, Boston Scientific Scimed and we filed suit for patent infringement against
       Johnson &amp;#038; Johnson and Cordis, alleging that its Cypher&amp;#174; drug-eluting stent infringes one of our
       patents. The suit was filed in the U.S. District Court for the District of Delaware seeking
       monetary and injunctive relief. Cordis filed a counterclaim against us alleging that the patent is
       not valid and is unenforceable. On July&amp;#160;1, 2005, a jury found that Johnson &amp;#038; Johnson&amp;#8217;s Cypher&amp;#174;
       drug-eluting stent infringes the patent and upheld the validity of the patent. On January&amp;#160;15, 2009,
       the U.S. Court of Appeals reversed the lower Court&amp;#8217;s decision and found the patent invalid.
   On February&amp;#160;12, 2009, we filed a request for a rehearing and a rehearing en banc with the U.S.
   Court of Appeals and on March&amp;#160;24, 2009, our request was denied. We are considering our options for
       further appellate review.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On May 12, 2004, we filed suit against
       two of Johnson &amp;#038; Johnson&amp;#8217;s Dutch subsidiaries, alleging that Cordis&amp;#8217; Bx Velocity&amp;#174; stent,
       Bx Sonic&amp;#174; stent,
       Cypher&amp;#174; stent, Cypher&amp;#174; Select stent, and Aqua T3 balloon delivery systems for those stents, and U-Pass
       angioplasty balloon catheters infringe one of our European patents. The suit was filed in the District Court of The
       Hague in The
       Netherlands seeking injunctive and monetary relief. On June 8, 2005, the Court found the Johnson &amp;#038; Johnson products
       infringe our patent and enjoined the sale of certain products. An appeal decision was received on March 15, 2007,
       finding the patent valid but not infringed. We appealed the finding and on March 6, 2009, the Dutch Supreme Court
       dismissed our appeal. On August 3, 2009, Johnson &amp;#038; Johnson filed a motion seeking damages for the wrongful enforcement
       of the injunction.&lt;br /&gt;&lt;br style="font-size: 6pt" /&gt;
   On August&amp;#160;5, 2004, we (through our subsidiary Schneider Europe GmbH) filed suit in the District
       Court of Brussels, Belgium against the Belgian subsidiaries of Johnson &amp;#038; Johnson, Cordis and
       Janssen Pharmaceutica alleging that Cordis&amp;#8217; Bx Velocity&amp;#174; stent, Bx Sonic&amp;#174; stent, Cypher&amp;#174; stent,
       Cypher&amp;#174; Select stent, Aqua T3&amp;#8482; balloon and U-Pass balloon infringe one of our European patents and
       seeking injunctive and monetary relief. On September&amp;#160;12, 2008, the District Court issued a decision
       and ruled that a technical expert be appointed. On December&amp;#160;1, 2008, we filed a partial appeal of
       the decision in the Brussels Court of Appeals. In December&amp;#160;2005, the Johnson &amp;#038; Johnson subsidiaries
       filed a nullity action in France. On January&amp;#160;25, 2008, we filed a counterclaim infringement action
       in France, and a hearing is scheduled for December&amp;#160;1, 2009. In January&amp;#160;2006, the same Johnson &amp;#038;
       Johnson subsidiaries filed nullity actions in Italy and Germany. On October&amp;#160;23, 2007, the German
       Federal Patent Court found the patent valid. We then filed a counterclaim infringement action in
       Italy and an infringement action in Germany. On February&amp;#160;10, 2009, the District Court of Dusseldorf
   issued a decision dismissing the German infringement action. On March&amp;#160;24, 2009, we filed an appeal
       with the Court of Appeals in Dusseldorf, Germany. A hearing was held in Italy on July&amp;#160;8, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On September&amp;#160;27, 2004, Boston Scientific Scimed filed suit against a German subsidiary of Johnson &amp;#038;
       Johnson alleging the Cypher&amp;#174; drug-eluting stent infringes one of our European patents. The suit was
       filed in Mannheim, Germany seeking monetary and injunctive relief. A hearing was held on September
       21, 2007, in Mannheim, Germany, and a further hearing is scheduled for August&amp;#160;7, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On November&amp;#160;29, 2007, Boston Scientific Scimed filed suit against a German subsidiary of Johnson &amp;#038;
       Johnson alleging the Cypher&amp;#174; and Cypher&amp;#174; Select drug-eluting stents infringe one of our European
       patents. The suit was filed in Mannheim, Germany seeking monetary and injunctive relief. On October
       17, 2008, the Court ruled that a technical expert be appointed to evaluate infringement. A hearing
       has been scheduled for August&amp;#160;7, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On September&amp;#160;25, 2006, Johnson &amp;#038; Johnson filed a lawsuit against us, Guidant and Abbott in the U.S.
   District Court for the Southern District of New York. The complaint alleges that Guidant breached
       certain provisions of the amended merger agreement between Johnson &amp;#038; Johnson and Guidant (Merger
       Agreement) as well as the implied duty of good faith and fair dealing. The complaint further
       alleges that Abbott and we tortiously interfered with the Merger Agreement by inducing Guidant&amp;#8217;s
       breach. The complaint seeks certain factual findings, damages in an amount no less than $5.5
   billion and attorneys&amp;#8217; fees and costs. On August&amp;#160;29, 2007, the judge dismissed the tortious
       interference claims against us and Abbott and the implied duty of good faith and fair dealing claim
       against Guidant. On February&amp;#160;20, 2009, Johnson &amp;#038; Johnson filed a motion to amend its complaint to
       reinstate its tortious interference claims against us and Abbott and to add additional breach
       allegations against Guidant. On March&amp;#160;27, 2009, we filed an opposition to the motion. A trial date
       has not yet been scheduled.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On each of May&amp;#160;25, June&amp;#160;1, June&amp;#160;22 and November&amp;#160;27, 2007, Boston Scientific Scimed and we filed
       suit against Johnson &amp;#038; Johnson and Cordis in the U.S. District Court for the District of Delaware
       seeking a declaratory judgment of invalidity of four U.S. patents owned by them and of
       non-infringement of the patents by our PROMUS&amp;#174; coronary stent system. On February&amp;#160;21, 2008, Cordis
       filed counterclaims for infringement seeking an injunction and a declaratory judgment of validity.
   On June&amp;#160;25, 2009, we amended our complaints to allege
       that the four patents owned by Johnson &amp;#038; Johnson and Cordis are unenforceable. A liability trial on
       all four suits is scheduled to begin on February&amp;#160;4, 2010. The Court has bifurcated damages and our
       unenforceability defenses. A separate trial on these issues will be scheduled after a final
       decision on any appeal following the liability trial.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On October&amp;#160;17, 2008, Cordis Corporation filed a complaint for patent infringement against us
       alleging that our TAXUS&amp;#174; Libert&amp;#233;&amp;#174; stent product, when launched in the United States, will infringe
       a U.S. patent owned by them. The suit was filed in the United States District Court of Delaware
       seeking monetary and injunctive relief. On November&amp;#160;10, 2008, Cordis filed a motion for summary
       judgment and on May&amp;#160;1, 2009, we filed a motion to dismiss the case. On May&amp;#160;26, 2009, Cordis
       dismissed its request for injunctive relief. On May&amp;#160;27, 2009, a hearing was held on the parties&amp;#8217;
       motions and on July&amp;#160;21, 2009, the District Court denied both parties&amp;#8217; motions.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Litigation with St. Jude Medical, Inc.&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Guidant Sales Corp., Cardiac Pacemakers, Inc. (CPI)&amp;#160;and Mirowski are plaintiffs in a patent
       infringement suit originally filed against St. Jude Medical, Inc. and its affiliates in November
       1996 in the District Court in Indianapolis. On March&amp;#160;1, 2006, the District Court issued a ruling
       related to damages which granted St. Jude&amp;#8217;s motion to limit damages to a subset of the accused
       products but which denied their motion to limit damages to only U.S. sales. On March&amp;#160;26, 2007, the
       District Court issued a ruling which found the patent infringed but invalid. On December&amp;#160;18, 2008,
       the Court of Appeals upheld the District Court&amp;#8217;s ruling of infringement and overturned the
       invalidity ruling. On January&amp;#160;21, 2009, St. Jude and we filed requests for rehearing and rehearing
       en banc with the Court of Appeals. On March&amp;#160;6, 2009 the Court of Appeals granted St. Jude&amp;#8217;s
   request
       for a rehearing en banc on a damages issue and denied our requests. The en banc hearing was held on
       May&amp;#160;29, 2009.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Litigation with Medinol Ltd.&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On September&amp;#160;25, 2002, we filed suit against Medinol alleging Medinol&amp;#8217;s NIRFlex&amp;#8482; and NIRFlex&amp;#8482; Royal
       products infringe a patent owned by us. The suit was filed in the District Court of The Hague, The
       Netherlands seeking cross-border, monetary and injunctive relief. On September&amp;#160;10, 2003, the Dutch
       Court ruled that the patent was invalid. On December&amp;#160;14, 2006, an appellate decision was rendered
       upholding the trial court ruling. On March&amp;#160;6, 2009, the Dutch Supreme Court reversed the appellate
       court decision and sent the case back to the appellate court for further proceedings.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Other Stent System Patent Litigation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On May&amp;#160;19, 2005, G. David Jang, M.D. filed suit against us alleging breach of contract relating to
       certain patent rights covering stent technology. The suit was filed in the U.S. District Court,
       Central District of California seeking monetary damages and rescission of the contract. After a
       Markman ruling relating to the Jang patent rights, Dr.&amp;#160;Jang stipulated to the dismissal of certain
       claims alleged in the complaint with a right to appeal. In February&amp;#160;2007, the parties agreed to
       settle the other claims of the case. On May&amp;#160;23, 2007, Jang filed an appeal with respect to the
       remaining patent claims. On July&amp;#160;11, 2008, the Court of Appeals vacated the District Court&amp;#8217;s
       consent judgment and remanded the case back to the District Court for further clarification. On
       June&amp;#160;11, 2009, the District Court ordered a stay of the action pursuant to the parties&amp;#8217; joint
       stipulation.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On August&amp;#160;6, 2008, Boston Scientific Scimed and we filed suit against Wall Cardiovascular
       Technologies, in the U.S. District Court for the District of Delaware seeking a declaratory
       judgment of invalidity and unenforceability due to inequitable conduct and prosecution history
       laches of a U.S. patent owned by them, and of non-infringement of the patent by our PROMUS&amp;#174;
       coronary stent system. On January&amp;#160;2, 2009, we filed an amended complaint to include noninfringement
       of the patent by our TAXUS&amp;#174; Libert&amp;#233;&amp;#174; stent delivery system and to add Cardio Holdings LLC as a
       defendant. On February&amp;#160;27, 2009, Wall and Cardio Holdings filed a motion to dismiss.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On March&amp;#160;16, 2009, OrbusNeich Medical, Inc. filed suit against us in the U.S. District Court for
       the Eastern District of Virginia alleging that our Libert&amp;#233;&amp;#174; coronary stent system infringes two
       U.S. patents owned by them. The complaint also alleges breach of contract and misappropriation of
       trade secrets and seeks monetary and injunctive relief. On April&amp;#160;13, 2009, we answered denying the
       allegations and filed a motion to transfer the case to Minnesota as well as a motion to dismiss the
       state law claims. On June&amp;#160;8, 2009, the case was transferred to the U.S. District Court for the
       District of Massachusetts.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Cardiac Rhythm Management (CRM)&amp;#160;Litigation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;Approximately 19 product liability class action lawsuits and more than 513 individual lawsuits
       involving approximately 822 individual plaintiffs remain pending in various state and federal
       jurisdictions against Guidant alleging personal injuries associated with defibrillators or
       pacemakers involved in certain 2005 and 2006 product communications. The majority of the cases in
       the United States are pending in federal court but approximately 125 cases are currently pending in
       state courts. On November&amp;#160;7, 2005, the Judicial Panel on Multi-District Litigation established
       MDL-1708 (MDL)&amp;#160;in the United States District Court for the District of Minnesota and appointed a
       single judge to preside over all the cases in the MDL. In April&amp;#160;2006, the personal injury
       plaintiffs and certain third-party payors served a Master Complaint in the MDL asserting claims for
       class action certification, alleging claims of strict liability, negligence, fraud, breach of
       warranty and other common law and/or statutory claims and seeking punitive damages. The majority of
       claimants allege no physical injury, but sue for medical monitoring and anxiety. On July&amp;#160;12, 2007,
       we reached an agreement to settle certain claims, including those associated with the 2005 and 2006
   product communications, which was amended on November&amp;#160;19, 2007. Under the terms of the amended
       agreement, subject to certain conditions,
   we will pay a total of up to $240&amp;#160;million covering up to
       8,550 patient claims, including almost all of the claims that have been consolidated in the MDL as
       well as other filed and unfiled claims throughout the United States. On June&amp;#160;13, 2006, the
       Minnesota Supreme Court appointed a single judge to preside over all Minnesota state court lawsuits
       involving cases arising from the product communications. The plaintiffs in those cases are eligible
       to participate in the settlement, and activities in all Minnesota State court cases are currently
       stayed pending individual plaintiff&amp;#8217;s decisions whether to participate in the settlement. Through
       the end of the second quarter, more than 8,100 claims have been approved for participation in the
       MDL settlement. As a result, through the end of the second quarter, we have made payments of
       approximately $229&amp;#160;million related to the MDL settlement and, if certain agreed-upon requirements
       are met, may make substantially all of the remaining $11&amp;#160;million payment during the third quarter
       of 2009. On April&amp;#160;6, 2009, the judge in the MDL issued an order dismissing with prejudice most of
       the plaintiffs&amp;#8217; claims which have been resolved through the settlement agreement. Further
       dismissal orders are expected as additional claimants are approved for participation in the
       settlement.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We are aware of more than 18 Guidant product liability lawsuits pending internationally associated
       with defibrillators or pacemakers, including devices involved in the 2005 and 2006 product
       communications. Six of those suits pending in Canada are putative class actions, four of which are
       stayed pending the outcome of two lead class actions. On April&amp;#160;10, 2008, the Court certified a
       class of persons in whom defibrillators were implanted in Canada and a class of family members with
       derivative claims. The second of these lead putative class actions encompasses all persons in whom
       pacemakers were implanted in Canada. On May&amp;#160;8, 2009, the Court certified a class of persons in whom
       pacemakers were implanted in Canada.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Securities Related Litigation&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On September&amp;#160;23, 2005, Srinivasan Shankar, on behalf of himself and all others similarly situated,
       filed a purported securities class action suit in the U.S. District Court for the District of
       Massachusetts on behalf of those who purchased or otherwise acquired our securities during the
       period March&amp;#160;31, 2003 through August&amp;#160;23, 2005, alleging that we and certain of our officers
       violated certain sections of the Securities Exchange Act of 1934. Four other plaintiffs, on behalf
       of themselves and all others similarly situated, each filed additional purported securities class
       action suits in the same Court on behalf of the same purported class. On February&amp;#160;15, 2006, the
       Court ordered that the five class actions be consolidated and appointed the
       Mississippi Public Employee Retirement System Group as lead plaintiff. A consolidated amended
       complaint was filed on April&amp;#160;17, 2006. The consolidated amended complaint alleges that we made
       material misstatements and omissions by failing to disclose the supposed merit of the Medinol
       litigation and DOJ investigation relating to the 1998 NIR ON&amp;#174; Ranger with Sox stent recall,
       problems with the TAXUS&amp;#174; drug-eluting coronary stent systems that led to product recalls, and our
       ability to satisfy FDA regulations concerning medical device quality. The consolidated amended
       complaint seeks unspecified damages, interest, and attorneys&amp;#8217; fees. The defendants filed a motion
       to dismiss the consolidated amended complaint on June&amp;#160;8, 2006, which was granted by the Court on
       March&amp;#160;30, 2007. On April&amp;#160;16, 2008, the First Circuit reversed the dismissal of only plaintiff&amp;#8217;s
       TAXUS&amp;#174; stent recall related claims and remanded the matter for further proceedings. On February&amp;#160;25,
       2009, the Court certified a class of investors who acquired our securities during the period
       November&amp;#160;30, 2003 through July&amp;#160;15, 2004. A trial has not yet been scheduled.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Governmental Proceedings &amp;#8212; Guidant&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In October&amp;#160;2005, Guidant received administrative subpoenas from the U.S. Department of Justice
       U.S. Attorney&amp;#8217;s offices in Boston and Minneapolis, issued under the Health Insurance Portability &amp;#038;
       Accountability Act of 1996. The subpoena from the U.S. Attorney&amp;#8217;s office in Boston requests
       documents concerning certain marketing practices for pacemakers, implantable cardioverter
       defibrillators, leads and related products arising prior to our acquisition of Guidant in 2006. The
       subpoena from the U.S. Attorney&amp;#8217;s office in Minneapolis requests documents relating to alleged violations of the Food, Drug, and Cosmetic Act
       occurring prior to our acquisition of Guidant involving Guidant&amp;#8217;s VENTAK PRIZM&amp;#174; 2 and CONTAK
       RENEWAL&amp;#174; and CONTAK RENEWAL 2 devices. Guidant is cooperating with the requests, including
       producing a significant volume of documents and, in the Minneapolis matter, providing witnesses for
       grand jury proceedings.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On October&amp;#160;24, 2008, we received a letter from the U.S. Department of Justice (DOJ)&amp;#160;informing us of
       an investigation relating to alleged off-label promotion of surgical cardiac ablation system
       devices to treat atrial fibrillation. We have divested the surgical cardiac ablation business and
       the devices at issue are no longer sold by us. On July&amp;#160;13, 2009, we became aware that a judge in
       Texas partially unsealed a &lt;i&gt;qui tam&lt;/i&gt; whistleblower complaint on which this investigation is based.
   The government has not yet decided whether to intervene in the suit. We are cooperating with the
       government&amp;#8217;s investigation.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On November&amp;#160;7, 2008, Guidant/Boston Scientific received a request from the Department of Defense
   (DOD), Defense Criminal Investigative Service and the Department of the Army, Criminal
       Investigation Command seeking information concerning sales and marketing interactions with
       physicians at Madigan Army Medical Center in Tacoma, Washington. Since that date, we have been
       cooperating with the DOD and the Department of Justice to review CRM&amp;#8217;s financial interactions with
       military personnel.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Other Proceedings&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On July&amp;#160;28, 2000, Dr.&amp;#160;Tassilo Bonzel filed a complaint naming certain of our Schneider Worldwide
       subsidiaries and Pfizer Inc. and certain of its affiliates as defendants, alleging that Pfizer
       failed to pay Dr.&amp;#160;Bonzel amounts owed under a license agreement involving Dr.&amp;#160;Bonzel&amp;#8217;s patented
       Monorail&amp;#174; balloon catheter technology. This and similar suits were dismissed in state and federal
       courts in Minnesota. On April&amp;#160;24, 2007, we received a letter from Dr.&amp;#160;Bonzel&amp;#8217;s counsel alleging
       that the 1995 license agreement with Dr.&amp;#160;Bonzel may have been invalid under German law. On October
       5, 2007, Dr.&amp;#160;Bonzel filed a complaint against us and Pfizer in Kassel, Germany, alleging the 1995
   license agreement is invalid under German law and seeking monetary damages. On June&amp;#160;12, 2009, the
       Court dismissed all but one of Dr.&amp;#160;Bonzel&amp;#8217;s claims and set a deadline of October&amp;#160;16, 2009, for Dr.
   Bonzel to file additional facts to support his remaining claim.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;FDA Warning Letters&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In January&amp;#160;2006, legacy Boston Scientific received a corporate warning letter from the FDA
       notifying us of serious regulatory problems at three of our facilities and advising us that our
       corporate-wide corrective action plan relating to three site-specific warning letters issued to us
       in 2005 was inadequate. We have identified
       solutions to the quality system issues cited by the FDA and have made significant progress in
       transitioning our organization to implement those solutions. The FDA reinspected a number of our
       facilities and, in October&amp;#160;2008, informed us that our quality system is now in substantial
       compliance with its Quality System Regulations. The FDA has approved all of our requests for final
       approval of Class&amp;#160;III submissions previously on hold due to the corporate warning letter and has
       approved all eligible requests for Certificates to Foreign Governments. The corporate warning
       letter remains in place pending final remediation of certain Medical Device Report filing issues,
       which we are actively working with the FDA to resolve. We have informed the FDA that we are ready
       for reinspection of the impacted sites.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;During the first quarter of 2009, we acquired a third-party sterilization facility currently
       subject to a warning letter from the FDA. The FDA has requested documentation and explanation
       regarding various corrective actions related to the facility. This information has been provided
       and we are currently working with the FDA to resolve remaining issues. We do not expect this
       warning letter to have an impact on the resolution of our corporate warning letter.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;&lt;i&gt;Matters Concluded Since January&amp;#160;1, 2009&lt;/i&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On April&amp;#160;2, 1997, Ethicon and other Johnson &amp;#038; Johnson subsidiaries filed a cross-border proceeding
       in The Netherlands alleging that the NIR&amp;#174; stent infringes a European patent licensed to Ethicon. In
       January&amp;#160;1999, Johnson &amp;#038; Johnson amended the claims of the patent and changed the action from a
       cross-border case to a Dutch national action. The Dutch Court asked the Dutch Patent Office for
       technical advice on the validity of the amended patent. On August&amp;#160;31, 2005, the Dutch Patent Office
       issued its technical advice that the amended patent was valid and on October&amp;#160;8, 2008, the Dutch
       Court found the patent valid. In light of a prior finding of
   noninfringement, we have determined
       not to appeal the finding.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On March&amp;#160;1, 2006, Medtronic Vascular, Inc. filed suit against Boston Scientific Scimed and us,
       alleging that our balloon products infringe four U.S. patents owned by Medtronic Vascular. The suit
       was filed in the U.S. District Court for the Eastern District of Texas seeking monetary and
       injunctive relief. On January&amp;#160;23, 2009, the parties executed a settlement and stand-still agreement
       settling the action.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On April&amp;#160;4, 2005, Angiotech and we filed suit against Sahajanand Medical Technologies Pvt. Ltd. in
       The Hague, The Netherlands seeking a declaration that Sahajanand&amp;#8217;s drug-eluting stent products
       infringe patents owned by Angiotech and licensed to us. On May&amp;#160;3, 2006, the Court found that the
       asserted patents were infringed and valid, and provided for injunctive and monetary relief. On
       January&amp;#160;27, 2009, the Court of Appeals affirmed that the patent was valid and infringed by
       Sahajanand.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On August&amp;#160;12, 2008, we filed suit for patent infringement against Medtronic, Inc. and certain of
       its subsidiaries alleging that the sale of certain balloon catheters and stent delivery systems
       infringe four U.S. patents owned by us. The complaint was filed in the United States District Court
       for the Northern District of California seeking monetary and injunctive relief. On January&amp;#160;23,
       2009, the parties executed a settlement and stand-still agreement and the case was dismissed on
       January&amp;#160;29, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On July&amp;#160;25, 2007, the U.S. District Court for the Northern District of California granted our
       motion to intervene in an action filed February&amp;#160;15, 2006 by Medtronic Vascular and certain of its
       affiliates against Advanced Cardiovascular Systems, Inc. and Abbott Laboratories. As a counterclaim
       plaintiff in this litigation, we were seeking a declaratory judgment of patent invalidity and of
       non-infringement by our PROMUS&amp;#174; coronary stent system relating to two U.S. patents owned
       by Medtronic. On January&amp;#160;23, 2009, the parties executed a settlement and stand-still agreement and
       the case was dismissed on January&amp;#160;30, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On August&amp;#160;12, 2008, we and Endovascular Technologies, Inc. filed suit for patent infringement
       against Medtronic, Inc. and certain of its subsidiaries alleging that the sale of Medtronic&amp;#8217;s AAA
       products infringe ten U.S. patents owned by the us. The complaint was filed in the United States
       District Court for the Eastern District of Texas, Tyler Division, seeking monetary and injunctive
       relief. On January&amp;#160;23, 2009, the parties executed a settlement and stand-still agreement and the
       case was dismissed on February&amp;#160;2, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On August&amp;#160;13, 2008, Medtronic, Inc. and certain of its subsidiaries filed suit for patent
       infringement against us, Boston Scientific Scimed, Inc., Abbott and certain of Abbott&amp;#8217;s
       subsidiaries alleging infringement of one U.S. patent owned by them. The complaint was filed in the
       United States District Court for the Eastern District of Texas, Marshall Division, seeking monetary
       and injunctive relief. On January&amp;#160;23, 2009, the parties executed a settlement and stand-still
       agreement and the case was dismissed on February&amp;#160;2, 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On March&amp;#160;26, 2002, we and our wholly owned subsidiary, Target Therapeutics, Inc., filed suit for
       patent infringement against Cordis alleging that certain detachable coil delivery systems infringe
       three U.S. patents, owned by or exclusively licensed to Target. The complaint was filed in the U.S.
   District Court for the Northern District of California seeking monetary and injunctive
       relief. On February&amp;#160;27, 2009, the parties executed a definitive settlement agreement and on March
       11, 2009, the case was formally dismissed.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On December&amp;#160;16, 2005, Bruce N. Saffran, M.D., Ph.D. filed suit against us alleging that our TAXUS&amp;#174;
       Express&amp;#174; coronary stent system infringes a patent owned by Dr.&amp;#160;Saffran. The suit was filed in the
       U.S. District Court for
   the Eastern District of Texas and seeks monetary and injunctive relief. On
       February&amp;#160;11, 2008, the jury found that our TAXUS&amp;#174; Express&amp;#174; and TAXUS&amp;#174; Libert&amp;#233;&amp;#174; stent products
       infringe Dr.&amp;#160;Saffran&amp;#8217;s patent and that the patent is valid. No injunction was requested, but the
       jury awarded damages of $431&amp;#160;million. The District Court awarded Dr.&amp;#160;Saffran $69&amp;#160;million in
       pre-judgment interest and entered judgment in his favor. On March&amp;#160;16, 2009, Bruce N. Saffran, M.D.,
       PhD. and we agreed to settle all outstanding litigation between us. As a result of this agreement,
       we recorded a litigation-related charge of $50&amp;#160;million during the first quarter of 2009, and made
       related payments of $45&amp;#160;million in the first half of 2009. A joint motion to dismiss the appeal
       with prejudice was granted on March&amp;#160;20, 2009. On April&amp;#160;3, 2009, a related complaint was also
       dismissed.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On April&amp;#160;19, 2007, SciCo Tec GmbH, filed suit against us and our subsidiary, Boston Scientific
       Medizintechnik GmbH, alleging certain of our balloon catheters infringe a German patent owned by
       SciCo Tec GmbH. The suit was filed in Mannheim, Germany. On February&amp;#160;7, 2009, the parties settled
       this suit and on April&amp;#160;21, 2009, the parties executed a definitive settlement agreement. We made
       the associated payment during the second quarter of 2009.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On January&amp;#160;16, 2007, the French Competition Council (Conseil de la Concurrence which is one of the
       bodies responsible for the enforcement of antitrust/competition law in France) issued a Statement
       of Objections alleging that Guidant France SAS (Guidant France) had agreed with the four other main
       suppliers of implantable cardioverter defibrillators (ICDs) in France to collectively refrain from
       responding to a 2001 tender for ICDs conducted by a group of seventeen (17)&amp;#160;University Hospital
       Centers in France. This alleged collusion is alleged to be contrary to the French Commercial Code
       and Article&amp;#160;81 of the European Community Treaty. On December&amp;#160;19, 2007, the Council found that the
       suppliers had violated competition law and assessed monetary fines, however, each of the suppliers
       were fined amounts considerably less than originally recommended. The French Ministry of the
       Economy and Finance filed an incidental recourse seeking aggravated sanctions against all
       defendants. On April&amp;#160;8, 2009, the Paris Court of Appeals dismissed the Minister&amp;#8217;s request for
       increased sanctions and confirmed the monetary fines previously
       assessed.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;With respect to ANCURE System claims, Guidant litigated coverage claims with its insurers in the
       Circuit Court of DuPage County Illinois and the Superior Court of Marion County, Indiana. Three of
       the insurers settled in 2008 and Guidant settled with the other insurers in March&amp;#160;2009. In April
       2009, both the Illinois and the Indiana lawsuits were dismissed.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On April&amp;#160;4, 2007, SciCo Tec GmbH filed suit against us alleging certain of our balloon catheters
       infringe a U.S. patent owned by SciCo Tec GmbH. The suit was filed in the U. S. District Court for
       the Eastern District of Texas seeking monetary and injunctive relief. On May&amp;#160;10, 2007, SciCo Tec
       filed an amended complaint alleging certain additional balloon catheters and stent delivery systems
       infringe the same patent. On February&amp;#160;7, 2009, the parties settled this suit and on April&amp;#160;20, 2009,
       the parties executed a definitive settlement agreement. On May&amp;#160;6, 2009, the District Court
       dismissed the case with prejudice.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;On August&amp;#160;3, 2007, Medinol submitted a request for arbitration against us, and our wholly owned
       subsidiaries Boston Scientific Ltd. and Boston Scientific Scimed, Inc., under the Arbitration Rules
       of the World Intellectual Property Organization pursuant to a settlement agreement between Medinol
       and us dated September&amp;#160;21, 2005. The request for arbitration alleges that our PROMUS&amp;#174; coronary
       stent system infringes five U.S. patents, three European patents and two German patents owned by
       Medinol. Medinol is seeking to have the patents declared valid and enforceable and a reasonable
       royalty. The September&amp;#160;2005 settlement agreement provides, among other things, that Medinol may
       only seek reasonable royalties and is specifically precluded from seeking injunctive relief. On
       June&amp;#160;29, 2008, the parties agreed that we can sell PROMUS&amp;#174; stent systems in the United States
       supplied to us by Abbott. A hearing on the European and German patents was scheduled to begin May
       11, 2009. On May&amp;#160;21, 2009, the parties reached a confidential settlement agreement and on June&amp;#160;15,
       2009, a Stipulation and Order was filed terminating the proceedings.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 13 - us-gaap:SegmentReportingDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;b&gt;NOTE M &amp;#8212; SEGMENT REPORTING&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;During the first quarter of 2009, we reorganized our international structure to provide more direct
   sales focus in the marketplace. Accordingly, we have revised our reportable segments to reflect the
   way we currently manage and view our business. Each of our reportable segments generates revenues
   from the sale of medical devices. As of June&amp;#160;30, 2009, we had four reportable segments based on
   geographic regions: the United States; EMEA, consisting of Europe, the Middle East and Africa;
   Japan; and Inter-Continental, consisting of Asia Pacific and the Americas. The reportable segments
   represent an aggregate of all operating divisions within each segment. We measure and evaluate our
   reportable segments based on segment net sales and operating income. We exclude from segment
   operating income certain corporate and manufacturing-related expenses, as our corporate and
   manufacturing functions do not meet the definition of a segment, as defined by FASB Statement No.
   131, &lt;i&gt;Disclosures about Segments of an Enterprise and Related Information. &lt;/i&gt;In addition, certain
   transactions or adjustments that our Chief Operating Decision Maker considers to be non-recurring
   and/or non-operational, such as amounts related to intangible asset impairment charges;
   acquisition-, divestiture-, litigation- and restructuring-related activities; as well as
   amortization expense, are excluded from segment operating income. Although we exclude these amounts
   from segment operating income, they are included in reported consolidated operating income and are
   included in the reconciliation below.
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We manage our international operating segments on a constant currency basis. Sales generated from
   reportable segments and divested businesses, as well as operating results of reportable segments
   and expenses from manufacturing operations, are based on internally derived standard currency
   exchange rates, which may differ from year to year, and do not include intersegment profits. We
   have reclassified previously reported segment results to be consistent with the 2009 presentation.
   Because of the interdependence of the reportable segments, the operating profit as presented may
   not be representative of the geographic distribution that would occur if the segments were not
   interdependent. A reconciliation of the totals reported for the reportable segments to the
   applicable line items in our unaudited condensed consolidated statements of operations is as
   follows:
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="52%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7"&gt;&lt;b&gt;Six Months Ended&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="7" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 8pt" valign="bottom"&gt;
       &lt;td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"&gt;&lt;i&gt;(in millions)&lt;/i&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2009&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="3"&gt;&lt;b&gt;2008&lt;/b&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Net sales&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;United States
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,194&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,088&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,364&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,205&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;EMEA
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;475&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;464&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;948&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;922&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Japan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;215&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;196&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;421&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;408&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Inter-Continental
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;182&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;168&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;349&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;323&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net sales allocated to reportable segments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,066&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,916&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;4,082&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,858&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Sales generated from divested businesses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;18&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;49&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Impact of foreign currency fluctuations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;90&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(3&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;164&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,074&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;2,024&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4,084&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;4,071&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&lt;b&gt;Income before income taxes&lt;/b&gt;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;United States
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;268&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;253&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;542&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;533&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;EMEA
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;224&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;220&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;452&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;437&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Japan
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;121&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;109&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;237&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;236&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Inter-Continental
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;83&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;80&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;162&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;156&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Operating income allocated to reportable
   segments
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;696&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;662&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,393&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,362&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Manufacturing operations
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(96&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(89&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(203&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(190&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Corporate expenses and currency exchange
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(142&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(98&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(268&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(166&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Intangible asset impairment charges; and
   acquisition-, divestiture-, litigation-, and
   restructuring- related net (charges)&amp;#160;credits
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(57&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(37&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(380&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;156&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Amortization expense
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(126&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(135&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(255&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(279&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;275&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;303&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;287&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;883&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other expense, net
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(95&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(203&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(204&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="right"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(321&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" nowrap="nowrap" align="left" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;180&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;100&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;83&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
       &lt;td align="right"&gt;&lt;b&gt;562&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td colspan="7" align="left" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 14 - us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE N&amp;#8212; NEW ACCOUNTING PRONOUNCEMENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;&lt;i&gt;Statement No.&amp;#160;141(R)&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In December&amp;#160;2007, the FASB issued Statement No.&amp;#160;141(R), &lt;i&gt;Business Combinations&lt;/i&gt;, a replacement for
   Statement No.&amp;#160;141. Statement No.&amp;#160;141(R) retains the fundamental requirements of Statement No.&amp;#160;141,
   but requires the recognition of all assets acquired and liabilities assumed in a business
   combination at their fair values as of the acquisition date. It also requires the recognition of
   assets acquired and liabilities assumed arising from contractual contingencies at their acquisition
   date fair values. Additionally, Statement No.&amp;#160;141(R) supersedes FASB Interpretation No.&amp;#160;4,
   &lt;i&gt;Applicability of FASB Statement No.&amp;#160;2 to Business Combinations Accounted for by the Purchase
   Method&lt;/i&gt;, which required research and development assets acquired in a business combination that had
   no alternative future use to be measured at their fair values and expensed at the acquisition date.
   Statement No.&amp;#160;141(R) now requires that purchased research and development be recognized as an
   indefinite-lived intangible asset until the completion or abandonment of the associated research
   and development efforts. We were required to adopt Statement No.&amp;#160;141(R) prospectively for any
   acquisitions on or after January&amp;#160;1, 2009. During the first half of 2009, we did not consummate any
   material business combinations.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Statement No.&amp;#160;161&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In March&amp;#160;2008, the FASB issued Statement No.&amp;#160;161, &lt;i&gt;Disclosures about Derivative Instruments and
   Hedging Activities&lt;/i&gt;, which amends Statement No.&amp;#160;133, &lt;i&gt;Accounting for Derivative Instruments and
   Hedging Activities&lt;/i&gt;, by
   requiring expanded disclosures about an entity&amp;#8217;s derivative instruments and
       hedging activities. Statement No.&amp;#160;161 requires increased qualitative, quantitative, and credit-risk
       disclosures, including (a)&amp;#160;how and why an entity uses derivative instruments, (b)&amp;#160;how derivative
       instruments and related hedged items are accounted for under Statement No.&amp;#160;133 and its related
       interpretations, and (c)&amp;#160;how derivative instruments and related hedged items affect an entity&amp;#8217;s
       financial position and financial performance. We adopted Statement No.&amp;#160;161 as of our first quarter
       ended March&amp;#160;31, 2009. Refer to &lt;i&gt;Note B &amp;#8212; Financial Instruments &lt;/i&gt;for more information.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Statement No.&amp;#160;165&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In May&amp;#160;2009, the FASB issued Statement No.&amp;#160;165, &lt;i&gt;Subsequent Events, &lt;/i&gt;which establishes general
       standards of accounting for and disclosure of events occurring after the balance sheet date, but
       before the financial statements are issued or available to be issued. Statement No.&amp;#160;165 also
       requires entities to disclose the date through which it has evaluated subsequent events and the
       basis for that date. We adopted Statement No.&amp;#160;165 for our second quarter ended June&amp;#160;30, 2009. Its
       adoption did not impact our results of operations or financial condition. Refer to&lt;br /&gt;
    &lt;i&gt;Note O &amp;#8212;
       Subsequent Events &lt;/i&gt;for more information regarding our evaluation of subsequent events.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 12pt"&gt;&lt;i&gt;Statement No.&amp;#160;168&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;In June&amp;#160;2009, the FASB issued Statement No.&amp;#160;168, &lt;i&gt;The FASB Accounting Standards
       Codification&lt;/i&gt;&lt;font style="font-family: Symbol"&gt;&amp;#212;&lt;/font&gt; &lt;i&gt;and the Hierarchy of Generally Accepted Accounting Principles, &lt;/i&gt;which
       establishes the FASB Accounting Standards Codification&lt;font style="font-family: Symbol"&gt;&amp;#212;&lt;/font&gt; as the single source of
       authoritative U.S. GAAP. The Codification&lt;font style="font-family: Symbol"&gt;&amp;#212;&lt;/font&gt; will supersede all existing non-SEC accounting and
       reporting standards. As a result, upon adoption, all references to accounting literature in our SEC
       filings will conform to the appropriate reference within the Codification&lt;font style="font-family: Symbol"&gt;&amp;#212;&lt;/font&gt;. We are required
       to adopt Statement No.&amp;#160;168 for our third quarter ending September&amp;#160;30, 2009. We do not expect the
       adoption of this standard to have an impact on our financial position or results of operations.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="January-01-2009_June-30-2009">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;html&gt;
   &lt;head&gt;&lt;/head&gt;
   &lt;body&gt;
   &lt;!-- Begin Block Tagged Note 15 - us-gaap:ScheduleOfSubsequentEventsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif"&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 18pt"&gt;&lt;b&gt;NOTE O&amp;#8212; SUBSEQUENT EVENTS&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="justify" style="font-size: 10pt; margin-top: 6pt"&gt;We have evaluated events occurring after the date of our accompanying unaudited condensed
   consolidated balance sheets through August&amp;#160;6, 2009, the date of the filing of this Quarterly Report
   on Form 10-Q. We did not identify any material subsequent events requiring adjustment to our
   accompanying unaudited condensed consolidated financial statements (recognized subsequent events).
   Those items requiring disclosure (unrecognized subsequent events) in the financial statements have
   been disclosed accordingly. Refer to &lt;i&gt;Note D &amp;#8212; Borrowings and Credit Arrangements&lt;/i&gt;, and &lt;i&gt;Note L &amp;#8212;
   Commitments and Contingencies &lt;/i&gt;for more information.
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;/body&gt;
   &lt;/html&gt;
</us-gaap:ScheduleOfSubsequentEventsTextBlock>
  <!-- End Block Tagged Note -->
  <bsx:GainOnDivestitures contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">250000000</bsx:GainOnDivestitures>
  <bsx:GainOnDivestitures contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</bsx:GainOnDivestitures>
  <bsx:GainOnDivestitures contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">0</bsx:GainOnDivestitures>
  <bsx:GainOnDivestitures contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">0</bsx:GainOnDivestitures>
  <bsx:LitigationRelatedCharges contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</bsx:LitigationRelatedCharges>
  <bsx:LitigationRelatedCharges contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</bsx:LitigationRelatedCharges>
  <bsx:LitigationRelatedCharges contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">287000000</bsx:LitigationRelatedCharges>
  <bsx:LitigationRelatedCharges contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">0</bsx:LitigationRelatedCharges>
  <bsx:LossOnContractTermination contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</bsx:LossOnContractTermination>
  <bsx:LossOnContractTermination contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</bsx:LossOnContractTermination>
  <bsx:LossOnContractTermination contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">16000000</bsx:LossOnContractTermination>
  <bsx:LossOnContractTermination contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">16000000</bsx:LossOnContractTermination>
  <bsx:PrepaidExpensesAndOtherCurrentAssets contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">645000000</bsx:PrepaidExpensesAndOtherCurrentAssets>
  <bsx:PrepaidExpensesAndOtherCurrentAssets contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">410000000</bsx:PrepaidExpensesAndOtherCurrentAssets>
  <bsx:PurchasedResearchAndDevelopment contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">29000000</bsx:PurchasedResearchAndDevelopment>
  <bsx:PurchasedResearchAndDevelopment contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">16000000</bsx:PurchasedResearchAndDevelopment>
  <bsx:PurchasedResearchAndDevelopment contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">17000000</bsx:PurchasedResearchAndDevelopment>
  <bsx:PurchasedResearchAndDevelopment contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">17000000</bsx:PurchasedResearchAndDevelopment>
  <dei:AmendmentFlag contextRef="January-01-2009_June-30-2009">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="January-01-2009_June-30-2009">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate contextRef="January-01-2009_June-30-2009">2009-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="January-01-2009_June-30-2009">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="January-01-2009_June-30-2009">0000885725</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_31Jul2009" unitRef="Shares" decimals="INF">1507498546</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="January-01-2009_June-30-2009">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="January-01-2009_June-30-2009">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2008" unitRef="USD" decimals="-5">16800000000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="January-01-2009_June-30-2009">Boston Scientific Corporation</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="January-01-2009_June-30-2009">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="January-01-2009_June-30-2009">Yes</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">1402000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
  <us-gaap:AccountsNotesAndLoansReceivableNetCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">1444000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">239000000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">213000000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">2612000000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">2021000000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">-53000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">-22000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">15944000000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">16009000000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">279000000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">135000000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">255000000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">126000000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AssetImpairmentCharges contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">10000000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">10000000</us-gaap:AssetImpairmentCharges>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">27139000000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">26193000000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">5452000000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">4796000000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2007" unitRef="USD" decimals="-6">1452000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2008" unitRef="USD" decimals="-6">1616000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">1641000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">1194000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">164000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-447000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies2009 xsi:nil="true" contextRef="TwelveMonthEnded_31Dec2008" />
  <us-gaap:CommitmentsAndContingencies2009 xsi:nil="true" contextRef="January-01-2009_June-30-2009" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2008" unitRef="Shares" decimals="INF">2000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Jun2009" unitRef="Shares" decimals="INF">2000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2008" unitRef="Shares" decimals="INF">1501635679</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Jun2009" unitRef="Shares" decimals="INF">1507258301</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">15000000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">15000000</us-gaap:CommonStockValue>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">1185000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">604000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">1237000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">630000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:DebtCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">2000000</us-gaap:DebtCurrent>
  <us-gaap:DebtCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">330000000</us-gaap:DebtCurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">911000000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">870000000</us-gaap:DeferredTaxAssetsNetCurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">2262000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">2165000000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:EarningsPerShareBasic contextRef="SixMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.28</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="January-01-2009_June-30-2009" unitRef="USDEPS" decimals="2">0.1</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USDEPS" decimals="2">0.1</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="SixMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.28</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USDEPS" decimals="2">0.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="January-01-2009_June-30-2009" unitRef="USDEPS" decimals="2">0.1</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USDEPS" decimals="2">0.1</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">2000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">4000000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:Goodwill contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">12421000000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">12425000000</us-gaap:Goodwill>
  <us-gaap:GrossProfit contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">2886000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">1420000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">2847000000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">1444000000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">562000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">100000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">83000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">180000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">142000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">2000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-62000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">22000000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">7244000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">6981000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestExpense contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">249000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">118000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">194000000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">92000000</us-gaap:InterestExpense>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">853000000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">878000000</us-gaap:InventoryNet>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">27139000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">26193000000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">3233000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">2750000000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">6743000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">5920000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">-860000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-487000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">498000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-640000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">524000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">680000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:OperatingExpenses contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">2003000000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">1117000000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">2560000000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">1169000000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">883000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">303000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">287000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">275000000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">294000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">272000000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">380000000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">186000000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">1727000000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">1944000000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">-72000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">-85000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-10000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">-3000000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">35000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromPreviousAcquisition contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">669000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
  <us-gaap:PaymentsForProceedsFromPreviousAcquisition contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">517000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">21000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">4000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">136000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">134000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2008" unitRef="Shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_30Jun2009" unitRef="Shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_31Dec2008" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="BalanceAsOf_30Jun2009" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_31Dec2008" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="BalanceAsOf_30Jun2009" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">0</us-gaap:PreferredStockValue>
  <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">1288000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">48000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">13000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">-912000000</us-gaap:ProceedsFromRepaymentsOfDebt>
  <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">-500000000</us-gaap:ProceedsFromRepaymentsOfDebt>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">47000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">50000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
  <us-gaap:ProfitLoss contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">420000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">98000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">145000000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">158000000</us-gaap:ProfitLoss>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">1728000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">1719000000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">497000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">253000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">520000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">263000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:RestructuringCharges contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">39000000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">10000000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">36000000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">13000000</us-gaap:RestructuringCharges>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">-2732000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">-2588000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RoyaltyExpense contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">94000000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">48000000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">98000000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">53000000</us-gaap:RoyaltyExpense>
  <us-gaap:SalesRevenueNet contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">4071000000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">2024000000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">4084000000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">2074000000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="SixMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">1315000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2008" unitRef="USD" decimals="-6">655000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="January-01-2009_June-30-2009" unitRef="USD" decimals="-6">1321000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Jun2009" unitRef="USD" decimals="-6">671000000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="BalanceAsOf_31Dec2008" unitRef="USD" decimals="-6">13174000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="BalanceAsOf_30Jun2009" unitRef="USD" decimals="-6">13414000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="SixMonthsEnded_30Jun2008" unitRef="Shares" decimals="-5">1502600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Jun2008" unitRef="Shares" decimals="-5">1505200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="January-01-2009_June-30-2009" unitRef="Shares" decimals="-5">1511600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="ThreeMonthsEnded_30Jun2009" unitRef="Shares" decimals="-5">1514500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="SixMonthsEnded_30Jun2008" unitRef="Shares" decimals="-5">1495800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2008" unitRef="Shares" decimals="-5">1497600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="January-01-2009_June-30-2009" unitRef="Shares" decimals="-5">1505800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="ThreeMonthsEnded_30Jun2009" unitRef="Shares" decimals="-5">1506800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Footnote Section-->
</xbrl>

